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Adoptive T-cell therapies (ACT) are emerging as essential treatments 
for cancer patients with immunologically active tumours, such as 
melanoma. Immunologically silent tumours, however, require 
further stimulation. Oncolytic viruses provide an intriguing option 
for immune system activation, as they induce danger signalling, 
immunogenic cell death, and tumour epitope spreading. This study 
investigated oncolytic adenovirus coding for human Tumour 
Necrosis Factor alpha (TNFα) and Interleukin 2 (IL2) as an enhancer 
for ACT. Syrian hamsters permissive for human adenovirus 
replication provided a model for tumour-infiltrating lymphocyte 
(TIL) therapy with oncolytic Ad5/3-E2F-d24-hTNFα-IRES-hIL2. 
Complementary studies were conducted in mice with replication-
incompetent viruses, providing data on adenovirally-delivered 
transgenes with receptor-modified T cells. Both replication-
incompetent viruses and oncolytic viruses were able to enhance the 
antitumour efficacy of ACT. Combined with TIL therapy, Ad5/3-
E2F-d24-hTNFα-IRES-hIL2 was able to cure 100% of the animals 
from tumours. The cured animals resisted tumour rechallenge, 
indicating formation of immunologic memory. TNFα enhanced 
chemokine expression in tumours, which attracted the infused cell 
graft into tumours. The transgenes also induced the presence of T 
cells, B cells, natural killer cells, and antigen-presenting cells in 
tumours, yet they lowered the levels of immunosuppressive M2 
macrophages. Moreover, local treatment induced systemic 
antitumour efficacy in non-injected distant tumours. Both tumours 
showed similar profiles in intratumoural immune cells, indicating 
systemic changes in the immune system. The animals treated with 
cytokine-armed viruses showed no signs of systemic toxicity. 
Furthermore, the local delivery of IL2 was safer and more efficient 
than systemic IL2 in regard to ACT, suggesting that adenovirally 
delivered IL2 could replace the toxic, systemic IL2 in ACT protocols. 
To conclude, oncolytic adenovirus coding for immunostimulatory 
cytokines is a potential enabler for T-cell therapies. 
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1 INTRODUCTION 
Cancer is the leading cause of mortality worldwide. The latest global 
statistics from 2012 reported the number of new cases to be 14.1 
million (Globocan 2012). Locally, cancer prevalence in Finland was 
33 000 new diagnoses in 2015, with a mortality rate of 12 000 
(Syöpärekisteri 2017). The mortality rates are staying stable, 
however, despite the constantly growing cancer incidence (Globocan 
2012). A great amount of research is performed to develop new 
treatments and to improve conventional therapies. 
Conventional cancer treatments, such as surgery, chemotherapy, 
and radiation therapy, are still first-line treatments for most cancer 
patients and often effective against local tumours. However, 
immunotherapies appear to be an emerging field along with the 
traditional treatments (Qiao et al. 2016). The roots of 
immunotherapies are usually dated in the late 19th century, when 
oncologist William Coley employed a mixture of inactivated bacteria 
(so called “Coley’s toxins”) to treat patients (Bickels et al. 2002). A 
mycobacterium-based tuberculosis vaccine, called Bacillus 
Calmette-Guérin, was successfully used in the 1970s to treat 
superficial bladder cancer (Morales et al. 1976). The treatment is now 
considered the standard of care and the mechanism-of-action is 
strongly related to immune reactions such as the release of 
immunostimulatory cytokines and chemokines from the tumour 
(Redelman-Sidi et al. 2014). Today, the immunotherapy concept 
includes a variety of treatment approaches from adoptive cell 
therapies to antibodies, cytokines, and oncolytic viruses (Farkona et 
al. 2016). 
The 2010s have been a golden decade for the emerging 
immunotherapies. Treatments such as Sipuleucel-T (a method to 
program a patient’s dendritic cells to act against prostate cancer) and 
monoclonal antibodies against checkpoint receptors Cytotoxic T-
lymphocyte associated protein 4 (CTLA-4) and Programmed death 1 
(PD-1) were approved for clinical use (Farkona et al. 2016). The first 
oncolytic virus for cancer treatment in the USA and Europe, herpes 
simplex virus Talimogene laherparepvec (T-Vec), was also approved 
 
15 
at the end of 2015 (Grigg et al. 2016). Altogether, 26 
immunotherapies have been approved to date, the latest being 
chimeric antigen receptor T cells (CAR-T) targeting CD19 on B-cell 
acute lymphoblastic leukemia patients in 2017 (Tang et al. 2018). 
New therapies are accepted one by one, but they are mainly 
effective against haematological cancer types and immunologically 
active melanomas that bear a high mutational load (Alexandrov et al. 
2013). Solid tumours often have an immunosuppressive 
microenvironment and are heterogeneous in nature, which is why 
one treatment approach is usually not enough. Immunotherapies, 
however, are able to counteract the immunosuppressive 
environment by stimulating the so-called cancer-immunity cycle 
described by Chen and Mellman (2013).  
The cancer-immunity cycle begins with immunogenic cell death 
and the release of cancer cell antigens. Next, dendritic cells and other 
antigen-presenting cells capture the tumour antigens and present 
them to cytotoxic T cells. T cells then traffic to and infiltrate tumours, 
recognize the malignant cells, and attack them (Chen & Mellman 
2013). Immunotherapeutics can induce each of these steps.  
Cancer immunotherapies aim to awaken the immune system and 
to enable the attack against escaped tumours. Conventional 
treatments, such as chemotherapy and radiation therapy, induce 
immunogenic cell death, but oncolytic viruses have similar yet more 
potent effects (Inoue & Tani 2014, Apetoh et al. 2007). Cytokines like 
granulocyte-macrophage colony-stimulating factor (GM-CSF) and 
interleukin 2 (IL2) enhance antigen presentation and T-cell 
activation. Monoclonal antibodies against CTLA-4 and PD-1 enhance 
T-cell activation and cytotoxicity, and adoptive T-cell therapies 
(ACT) increase the recognition of cancer cells (Chen, Mellman 2013). 
This study combined ACTs with cytokine-armed oncolytic 
adenoviruses to make solid tumours less immunosuppressive and to 
create strong but safe immune reactions against solid tumours by 
inducing the cancer-immunity cycle.  
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REVIEW OF THE LITERATURE 
1.1 TUMOUR ESCAPE FROM THE IMMUNE 
SYSTEM 
The first suggestions that the immune system might prevent tumour 
formation date back to the beginning of the 20th century. The 
statements were formulated into a cancer immunosurveillance 
hypothesis in the late 1950s (Dunn et al. 2002, Burnet 1957). More 
data supporting the hypothesis accumulated later on, and it was 
acknowledged that the interaction between a tumour and the 
immune system could even promote development of tumours 
invisible from the immune system (Dunn et al. 2002). Today, 
avoiding immune system destruction counts as one of the cancer 
hallmarks, referring to the universality of tumour cells having 
developed a mechanism to escape from the immune system 
(Hanahan, Weinberg 2011). 
1.1.1 CANCER IMMUNOEDITING 
The theory of cancer immunoediting explains the phenomenon of 
tumours escaping the immune system (Dunn et al. 2002). The 
theory, which takes the concept of immunosurveillance one step 
forward, comprises three phases: elimination, equilibrium, and 
escape. Innate immunity cells, such as natural killer (NK) cells, NK 
T cells, and γδ T cells, recognise malignant cells in the elimination 
phase and start producing interferon (IFN) γ. IFNγ then recruits 
more NK cells and antigen-presenting cells, such as dendritic cells 
and macrophages, into the cancerous tissue. Simultaneously, IFNγ 
promotes apoptosis in cancer cells and prevents angiogenesis (Dunn 
et al. 2002). 
CD4+ and CD8+ T cells activate and traffic towards the tumour 
due to antigen presentation by the dendritic cells. Cytotoxic T cells 
kill sensitive cancer cells but, according to Darwinian selection, the 
cancer cell population shifts towards resistance during the 
equilibrium phase. Finally, the clones that are resistant to 
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elimination start to dominate during the escape phase. As a result, 
an observable tumour mass invisible from the immune system starts 
to form (Dunn et al. 2002). 
1.1.2 CANCER IMMUNE EVASION 
The escaped cancer cells enhance the invisibility by developing an 
immunosuppressive microenvironment. The cells in a tumour 
microenvironment secrete soluble factors that create favourable 
conditions for immunosuppressive cells and directly suppress 
immune cell activation. The changes in the immune cell milieu 
comprise a dominance of helper T cell phenotype Th2 over Th1, the 
dysfunction of antigen-presenting cells, impaired cytotoxicity of 
CD8+ T cells and NK cells, and induction of immunosuppressive 
regulatory T cells (Treg), M2 macrophages, and myeloid-derived 
suppressor cells (MDSC). Moreover, cancer cells can directly inhibit 
cytotoxicity and proliferation of CD8+ effector cells by activating 
checkpoint inhibitors, such as PD-1 or CTLA-4 (Wang & DuBois 
2015). 
1.1.2.1 Soluble factors 
Cancer cells often secrete soluble factors that suppress the 
differentiation and maturation of immune cells or induce 
immunosuppressive cell phenotypes (Kim et al. 2007). Such factors 
include, for example, Vascular Endothelial Growth Factor (VEGF), 
IL10, Transforming Growth Factor (TGF) β, Prostaglandin E2 
(PGE2), FasL, and CCL21 (Shields et al. 2010, Kim et al. 2007). 
Moreover, factors like indoleamine 2,3‑dioxygenase (IDO) and 
tryptophan-2,3-dioxygenase 2 (TDO) deplete tryptophan, an 
essential amino acid for T-cell activity, from the tumour micro-
environment (Pilotte et al. 2012). 
VEGF, IL10, and PGE2 together induce the expression of 
apoptosis mediator FasL, which leads to induction of Tregs and 
suppression of cytotoxic CD8+ T cells (Motz et al. 2014). As a single 
factor, in addition to stimulating angiogenesis and in that way 
promoting tumour development, VEGF inhibits dendritic cell 
maturation, which is a crucial promoter for T cell activation 
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(Gabrilovich et al. 1998). IL10 has a dual role as immune suppressor 
and activator. IL10 traditionally relates to inhibition of helper and 
cytotoxic T cells, but it also stimulates T cells and NK cells (Dennis et 
al. 2013). High IL10 levels in serum, however, relate to poor 
prognosis in cancer patients, indicating the dominance of 
suppressive functions (Zhao et al. 2015). Like IL10, PGE2 inhibits 
proliferation and activation of CD4+ helper-type T cells (He & Stuart 
1999).  
Regarding immunosuppression, FasL has similar functions to 
TGFβ, which promotes Treg induction and suppresses CD8+ effector 
cells but also downregulates NK-cell and B-cell functions and shifts 
macrophage population phenotype towards immunosuppressive M2 
(Beck et al. 2001). CCL21 additionally induces Tregs by altering the 
cytokine profile in tumours and promotes MDSC tumour infiltration 
(Shields et al. 2010). These two cell types are the major regulatory 
cell types in immunological reactions. 
1.1.2.2 Suppressive immune cells 
Immunosuppressive cells are essential in maintaining self-tolerance 
and preventing autoimmunity by suppressing immune responses. 
Regarding cancer, the presence of these cells, however, prevents 
immune reactions against tumours. Such cells include Tregs, 
MDSCs, and M2 phenotype macrophages. 
Among the population of T cells, Tregs are distinguished by the 
expression of cell markers CD4, FoxP3, and CD25. They suppress the 
activity of effector T cells, NK cells, and dendritic cells via direct cell-
to-cell interaction and by secreting IL10 and TGFβ (Wang & DuBois 
2015). Patients with ovarian, esophageal, gastric, or colorectal cancer 
show elevated numbers of Tregs in their blood and tumours, and 
their presence in tumours correlates with poor prognosis (Mizukami 
et al. 2008, Kono et al. 2006, Curiel et al. 2004, Ichihara et al. 2003, 
Wolf et al. 2003). 
A high number of Tregs also correlates with a high number of 
MDSCs (Gabitass et al. 2011). MDSCs have a close relation to both 
Tregs and M2-like macrophages: MDSCs induce Treg activation and 
expansion and skew macrophage differentiation towards M2 
phenotype (Gabrilovich et al. 2012). Elevated MDSC numbers in 
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tumours and in blood circulation correlate with increased metastatic 
load, clinical stage of a cancer, and poor prognosis in several cancer 
types, including breast, colorectal, esophageal, gastric, and 
pancreatic cancers (Sun et al. 2012, Gabitass et al. 2011, Diaz-
Montero et al. 2009).  
The immunosuppressive effects of MDSCs comprise four 
strategies, which mainly affect T-cell functionality (Gabrilovich et al. 
2012). First, they drive T-cell growth arrest by depleting L-arginine 
and L-cysteine from the tumour microenvironment (Srivastava et al. 
2010, Rodriguez et al. 2004). Second, they produce reactive oxygen 
and nitrogen species impairing T-cell signalling (Mazzoni et al. 
2002). Third, the expression of ADAM17 and peroxynitrite by 
MDSCs limit the T-cell migration into lymph nodes and tumour 
stroma, respectively (Molon et al. 2011). Finally, the MDSCs express 
IFNγ, IL10, and TGFβ, which promote Treg differentiation and 
proliferation (Gabrilovich et al. 2012). 
M2-like macrophages also express IL10 and TGFβ (Gabrilovich et 
al. 2012). Macrophages gain the M2 phenotype in the presence of 
IL4, IL10, IL13, and glucocorticoid hormones (Gabrilovich et al. 
2012). They are associated with poor survival, at least among classic 
Hodgkin’s lymphoma patients, and they promote metastasis 
formation in breast cancer (Steidl et al. 2010, Qian et al. 2009). The 
soluble immunosuppressive factors secreted by the M2-like 
macrophages are the main cause for the M2-mediated 
immunosuppression (Gabrilovich et al. 2012). In addition, M2-like 
macrophages express PD-L1, which impairs T-cell activity when 
binding to its receptor, checkpoint inhibitor PD-1 (Kuang et al. 
2009). 
1.1.2.3 Checkpoint inhibitors 
Cytotoxic CD8+ cells express safe-switch receptors – checkpoint 
inhibitors – that inhibit the activity and proliferation of the cell. 
Cancer cells, however, are able to utilize these receptors when 
escaping from immunosurveillance (Wang & DuBois 2015). The two 
most investigated checkpoint inhibitors besides TIM-3 and LAG-3 
are PD-1 and CTLA-4, against which there are approved blocking 
antibodies for treatment of melanoma (Farkona et al. 2016). 
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Antigen-presenting cells, including cancer cells, are able to inhibit 
T cells via PD-1 by expressing its ligands PD-L1 or PD-L2. Of the 
soluble immunosuppressive factors, at least PTEN and IFNγ induce 
the expression of PD-L1, and IL10 and FasL drive T-cell apoptosis 
upon checkpoint activation (Song et al. 2013, Dong et al. 2002). 
Elevated expression of the ligands has been detected broadly among 
different cancer types, and it usually associates with poor prognosis 
(Zhu et al. 2017, Song et al. 2013, Cao et al. 2011, Hamanishi et al. 
2007, Ohigashi et al. 2005, Thompson et al. 2005). 
Contrary to PD-1, CTLA-4 is usually activated by antigen-
presenting cells other than cancer cells. Mainly dendritic cells 
express CD80 and CD86, which bind either to T-cell activating 
costimulatory receptor CD28 or to CTLA-4 causing T-cell inhibition 
(Walker & Sansom 2015). Hence, the competition between these two 
receptors determines the faith of a T cell: If CTLA-4 is blocked by an 
antibody, the cell will activate upon encountering an antigen-
presenting cell (Walker & Sansom 2015). 
CTLA-4 is also widely expressed on Tregs, which can inhibit the 
activation of conventional T cells via competition over CD80 and 
CD86. Moreover, Tregs are able to remove these ligands from 
antigen-presenting cells, preventing the activation of conventional T 
cell expressing CD28 (Walker & Sansom 2015). This complex 
interaction between checkpoint inhibitors, immunosuppressive 
cells, and soluble factors has an important function in preventing 
autoimmunity but also in protecting cancer. Immunotherapies, such 
as ACT, oncolytic viruses, and cytokine treatments, are crucial for 
resetting the immune system in tumour microenvironment. 
1.2 ADOPTIVE T-CELL THERAPY 
ACTs are based on patient-derived immune cells that are modified 
and expanded before administrating them back into the patient 
(Rosenberg & Restifo 2015). The cells derive from the patient’s 
peripheral blood or straight from the tumour. If extracted from the 
blood, a population of T cells becomes tumour-specific when 
modified to express tumour-associated, antigen-specific T cell 
receptors (TCR) or chimeric antigen receptors (CAR-T). Tumour-
infiltrating lymphocytes (TILs) have the ability to recognize the 
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tumour by nature and, thus, can also be used as such after 
purification and expansion. Traditionally, a patient receives the cells 
after preconditioning with chemotherapeutics and postconditioning 
with IL2 to optimize the cell graft function (Rosenberg & Restifo 
2015). Both regimens, however, may cause toxic adverse events 
(Morgan et al. 2010, Brentjens et al. 2009, Schwartz et al. 2002). 
Especially TIL graft infusion itself is usually tolerable and does not 
cause severe adverse events (Cruz et al. 2010). 
1.2.1 TUMOUR-INFILTRATING LYMPHOCYTES 
The simplified idea behind TIL therapy is to extract effector T cells 
from a tumour, expand and activate them in a laboratory, and 
administer them back to the patient to provoke an attack against the 
tumour (Figure 1) (Lee & Margolin 2012). T cells derived from 
enzymatically or mechanically disrupted tumour extracts are 
expanded with IL2 for a maximum of five weeks, after which the cells 
are activated with a rapid expansion protocol. Anti-CD3 antibody 
and irradiated feeder cells induce the rapid expansion over two 
weeks. The cell number is expanded up to 2 000 fold before 
administration back to the patient (Dudley et al. 2003). The success 
rate for growing TILs from extracts seemed problematic in the past, 
but today the cells are extractable from nearly every sample (Besser 
et al. 2009). 
A standard protocol has been shortened to produce so-called 
young TILs to avoid loss of T-cell activity during expansion (Itzhaki 
et al. 2011, Dudley et al. 2010, Tran et al. 2008). Nevertheless, the 
young TILs do not seem to be more efficient than the standard or 
CD8-enriched TILs, but they are easier to produce, have longer 
telomeres, and express more effector memory cell markers, such as 
CD27 and CD28 (Dudley et al. 2013, Donia et al. 2012, Itzhaki et al. 
2011, Tran et al. 2008). 
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Figure 1. Simplified schematic presentation of TIL therapy. First, a tumour biopsy 
is acquired from a patient (1.). Next, cytotoxic CD8+ cells are extracted from the biopsy 
and expanded in a laboratory in the presence of IL2 (2.). After activation with IL2 and 
the anti-CD3 antibody, the cells are infused back into the patient often after 
lymphodepleting chemotherapy and IL2 administration (3.). Figure adopted from Lee 
& Margolin 2012. 
The TIL-treatment protocol usually includes lympho-depleting pre-
conditioning with chemotherapeutics like cyclophosphamide and 
fludarabine to clear the patient’s body from endogenous T cells 
(Itzhaki et al. 2013). High-dose post-conditioning with IL2 improves 
the cell graft survival, but both of these regimens are toxic for the 
patients (Itzhaki et al. 2013, Schwartz et al. 2002). Meanwhile, TIL-
treatment itself appears safe with mild adverse events (Jiang et al. 
2015, Dudley et al. 2013, Radvanyi et al. 2012). 
The first clinical trial with TILs, performed by Rosenberg et al. 
between the late 1980s and early 1990s, ended up with overall 
objective response rate of 34%, comprising complete responders and 
patients whose tumours shrank more than 50% (Rosenberg, Yannelli 
et al. 1994). Clinical trials on metastatic melanoma with different 
pre- and post-conditioning regimes have later shown overall 
response rates up to 72% (Pilon-Thomas et al. 2012, Radvanyi et al. 
2012, Dudley et al. 2008). Moreover, complete responders seem to 
have long-term benefits from the treatment, since up to 93% of them 
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are alive after five years (Rosenberg et al. 2011). Importantly, TIL 
treatment also benefits patients who have failed other 
immunotherapies (Besser et al. 2013). 
In addition to melanoma, TIL trials have been conducted in 
hepatocellular carcinoma, non-small cell lung carcinoma, ovarian 
cancer, and renal cell carcinoma (Jiang et al. 2015, Andersen et al. 
2015, Ratto et al. 1996). TIL reactivity was increased in cervical 
cancer patients by selecting papillomavirus-reactive TILs for the 
treatment (Stevanovic et al. 2015). However, immunologically active 
melanoma shows currently the most promising results. In other 
indications, TIL therapy results in prolonged survival but complete 
responses are rare (Andersen et al. 2015).  
The main problem for TIL therapy efficacy is poor trafficking of 
the cell graft into the tumour. Most importantly, tumours need to 
have established vasculature through which lymphocytes can arrive 
at the tumour site (Sackstein et al. 2017). Peritumoural blood vessels 
guide the lymphocytes to the tumour margins, but the intratumoural 
vasculature is often inadequately structured.  The second important 
player in lymphocyte migration is the expression of chemokines that 
attract the cells to invade a tissue (Sackstein et al. 2017). Preclinical 
studies show that transducing TILs with a chemokine receptor, such 
as CXCR2, enhances the trafficking of the TILs into a tumour (Peng 
et al. 2010). Another approach is to stimulate chemokine expression 
in a tumour with immunostimulatory molecules, such as cytokines 
and pro-inflammatory agents (Atsumi et al. 2014). 
In addition to improved trafficking, the enrichment of the right 
populations from a heterogenic T-cell pool enhances TIL 
functionality (Cohen et al. 2015). Only a fraction of epitopes 
recognized by TILs is tumour associated, and the activity of the cells 
can regress during expansion (Andersen et al. 2012). The rest of the 
TILs recognize neoantigens, viruses, or currently unknown targets 
(Cohen et al. 2015, Robbins et al. 2013, Andersen et al. 2012). 
1.2.2 T CELL RECEPTOR-MODIFIED CELLS 
As TILs are a polyclonal population of T cells recognizing different 
tumour associated antigens, genetic modifications turn peripheral T 
cells into a homogenous population of cells (Lagisetty & Morgan 
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2012). T cells are modified to express a specific TCR that recognises 
tumour antigens that human leukocyte antigen (HLA) complex 
presents on malignant cells. Retroviral or lentiviral vectors enable 
the genetic engineering and the personalisation of the treatment 
(Lagisetty & Morgan 2012). 
The TCR engineering starts with the isolation of tumour-reactive 
T cells from a patient (Lagisetty & Morgan 2012). After receptor 
analysis, retroviral or lentiviral vectors deliver the receptor genes 
into unspecific T cells, for example, to blood mononuclear 
lymphocytes (Clay et al. 1999). Transduced T cells retain their 
natural abilities to act and proliferate and when the cells encounter 
their specific antigen, they respond by secreting cytokines and 
attacking the target cells (Zhao et al. 2007). 
Some tumours lack TILs or a tumour might be difficult to reach, 
so it is not always possible to extract TCR genes from tumour-
reactive cells. TCRs can be produced in gene-engineered mice or with 
phage display technology in these cases (Zhao et al. 2007, 
Stanislawski et al. 2001). The transgenic mice having HLA system 
can be immunised against known tumour-associated antigens and 
the genes for TCRs isolated (Lagisetty & Morgan 2012). The affinity 
of TCRs can be tested and optimised with the phage display method 
before transfer to T cells (Li et al. 2005). 
The first TCR transfer to blood mononuclear lymphocytes 
resulting in reactivity against melanoma cell lines was successful in 
the late 1990s (Clay et al. 1999). Melanoma, having a high mutational 
load and well-characterised tumour-associated antigens, is one of 
the most popular targets for TCR therapy (Alexandrov et al. 2013). 
The first phase I trial against melanoma antigen MART-1, published 
in 2006, resulted in responses in 13% (two out of 15) of the patients 
(Morgan et al. 2006). Another trial targeting MART-1 concluded 
with objective response rate of 30% but also with on-target, off-
tumour toxicities such as uveitis and hearing loss (Johnson et al. 
2009).  
Other frequent targets for melanoma TCR therapy are gp100 and 
NY-ESO-1. Targeting these antigens has resulted in response rates of 
19% (three out of 16) and 45% (five out of 11), respectively (Robbins 
et al. 2011, Johnson et al. 2009). NY-ESO-1 TCR therapy also had an 
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effect without toxicity on four out of six patients with synovial cell 
sarcoma (Robbins et al. 2011).  
In addition to melanoma and synovial cell carcinoma, TCR trials 
have been conducted on colorectal cancer against carcinoembryonic 
antigen for three patients, resulting in a progressive disease by six 
months in two patients that initially responded (Parkhurst et al. 
2011). The treatment also caused inflammatory colitis in all patients. 
Targeting MAGE-A3 in nine patients with metastatic cancers 
resulted in neurological adverse events for four patients, killing two 
and benefiting five patients (Morgan et al. 2013). TCRs against 
MAGE-A4 in ten esophageal cancer patients resulted in short-term 
benefits for seven patients and long-term benefits for two without 
serious adverse events (Kageyama et al. 2015). 
Key issues for an effective TCR therapy are a stable expression of 
the transduced gene, an abundant number of TCRs on a cell surface, 
and the affinity and specificity of the TCR against the antigen 
(Uttenthal et al. 2012). The affinity can be increased, for example, by 
substituting one or two amino acids in the antigen-binding region of 
a TCR (Dunn et al. 2006, Li et al. 2005). The murine versions of TCRs 
or hybrids with murine constant regions and human variable 
domains enhance the affinity in some cases (Johnson et al. 2009, 
Cohen et al. 2006). This might, however, raise a concern regarding 
neutralizing antibodies against foreign epitopes. Davis et al. (2010) 
studied serum samples from two different trials embodying murine 
TCRs against gp100 and p53 and discovered that 23% of the patients 
had developed neutralizing antibodies against these TCRs. The 
development of antibodies, however, did not correlate with the 
treatment outcome or cell persistence. 
The transferred cells can persist in a patient for at least a month 
and even up to a year, if the patient receives preconditioning with 
lymphodepleting chemotherapy and postconditioning with IL2 
(Johnson et al. 2009, Morgan et al. 2006). Moreover, the transferred 
T-cell phenotype influence the persistence. In mouse studies, for 
example, CD4+ cells persisted longer in the animals than CD8+ cells 
did with the same TCR modification (Engels et al. 2012). 
Furthermore, central memory or naïve T cells seem to persist longer 
in vivo than the effector cells (Hinrichs et al. 2009, Berger et al. 
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2008). The persistence of TCR-modified T cells is generally better 
than that of CAR-Ts (Uttenthal et al. 2012). 
1.2.3 CHIMERIC ANTIGEN RECEPTOR T CELLS 
CAR-Ts recognize antigens expressed on the cancer cell surface 
directly in contrast to TCRs that require activation by HLA complex-
mediated antigen presentation (Rosenberg & Restifo 2015). In 
addition to tumour-specific proteins, CAR-Ts can recognize 
carbohydrates and glycolipids, giving the target selection more 
flexibility (Dotti et al. 2014). Thus, CAR-Ts have the characteristics 
of a monoclonal antibody combined with replication-competent T 
cells (Dotti et al. 2014).  
The ectodomain of a CAR-T contains a single-chain variable 
fragment of an antibody that recognizes a tumour antigen, and one 
or more TCR signalling parts that activate the T cell (Figure 2) 
(Dotti et al. 2014, Eshhar et al. 1993). The number of intracellular 
signalling domains determines the classification of the CAR-Ts into 
first, second, or third generation (Dotti et al. 2014). CAR-Ts can also 
be modified, for example, to express immunostimulatory agents or 
receptors for cytokines that further activate the cells (Jackson et al. 
2016).  
 
Figure 2. The structure of different generation CAR-T receptors. The extracellular 
domain of a CAR-T receptor has a single-chain variable fragment (scFV) of an 
antibody. Intracellular domains mediate the activation signals when the antibody 
fragment binds to its antigen. The cells can be modified to express cytokine receptors 




Impressive response rates (up to 90%) to CAR-T therapies have been 
achieved especially in haematological malignancies, and the first 
products targeting CD19, Tisagenlecleucel and Axicabtagene 
ciloleucel, were approved in 2017 for B-cell lymphoma patients 
(Tang et al. 2018, Jackson et al. 2016). CAR-Ts targeting B-cell 
antigen CD19 have a proven efficacy against different types of 
leukemias and lymphomas, such as acute lymphoplastic leukemia, 
chronic lymhocytic leukemia, and non-Hodgin lymphoma (Brudno 
et al. 2016, Jackson et al. 2016, Porter et al. 2015, Brentjens et al. 
2013). Treatment of solid tumours, however, is more challenging 
because of heterogeneity in the cell surface markers and more 
complex tumour microenvironment (Jackson et al. 2016). 
Potential markers for solid tumours are, for example, HER2, 
EGFR, and GD2 (Newick et al. 2017); however, the best results from 
the conducted clinical trials are modest. Treatment of liver 
metastases with CEA-targeted CAR-Ts halted tumour progression in 
one out of six patients (Katz et al. 2015). Four out of 17 patients with 
HER2-positive sarcoma resulted in a stable disease when treated 
with HER2-specific CAR-Ts (Ahmed et al. 2015). Treatment of non-
small-cell lung cancer targeting EGFR led to partial responses in two 
out of 11 patients (Feng et al. 2016). The only complete responses 
reported thus far occurred in neuroblastoma patients when targeting 
GD2: Three out of 11 patients obtained complete remissions (Louis 
et al. 2011).  The treatment with CAR-Ts in these trials did not cause 
severe adverse events. 
A common adverse event encountered with CAR-T therapy of 
haematological cancers is cytokine release syndrome (Brudno & 
Kochenderfer 2016). Cell infusion causes elevation in IL6, IFNγ, IL2, 
IL8, and IL10 serum levels, among others (Brudno & Kochenderfer 
2016). The symptoms include fever, rash, and nausea, in addition to 
more severe cardiovascular and neurologic adverse events (Lee et al. 
2014). The symptoms are controllable to some extent with 
corticosteroids or tocilizumab, an antibody against IL6 receptor, but 
in the worst cases, they threaten the patient’s life (Maude et al. 2014). 
Off-target toxicities and on-target off-tumour toxicities additionally 
cause adverse events (Brudno & Kochenderfer 2016). 
The challenge of CAR-T therapy is to select an antigen that is 
common solely on tumour to avoid on-target, off-tumour toxicities. 
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The prediction of off-tumour effects is difficult, because the 
preclinical studies are done in animals. The studies often employ 
species-specific CAR-Ts, since the ectodomains in human CAR-Ts 
rarely recognize the corresponding non-human molecule, or the 
expression of the target might differ between the species (Dotti et al. 
2014). The target antigen should also be present on the majority of 
cancer cells to minimize the risk for immune escape. One way to 
lower the off-target toxicities and the risk for immune escape is to 
use a bispecific ectodomain that recognizes two different antigens 
(Zah et al. 2016, Hegde et al. 2016). The use of two different CAR-T 
populations might also prevent immune escape and increase efficacy 
(Feng et al. 2017). 
The efficacy of a CAR-T depends on the affinity of the single chain 
variable fragment and the distance of the recognized epitope from 
the target cell surface (Haso et al. 2013, Hudecek et al. 2013). A 
limitation of the first generation CAR-Ts’ efficacy has been short 
persistence and weak proliferation of the cells in a patient (Jensen et 
al. 2010). Second and third generation CAR-Ts have better efficacy 
and differences between these two are negligible (Jackson et al. 
2016). To improve CAR-T efficacy, the cells could be administered, 
for example, with checkpoint inhibitor antibodies, oncolytic viruses, 
or cytokines (Newick et al. 2017). 
1.3 CYTOKINES IN IMMUNOTHERAPY 
Immune cells secrete cytokines to regulate and modify 
immunological reactions, cell proliferation and differentiation, 
angiogenesis, and cell death (Vacchelli et al. 2015). Regarding 
recombinant cytokines in the treatment of cancer, the Food and Drug 
Administration (FDA) approved IFNα for hairy cell leukemia in 1986 
and IL2 for metastatic renal cell carcinoma in 1992 and later for 
melanoma (Floros & Tarhini 2015). In addition to the approved 
cytokines, clinical work is ongoing with several other cytokines, such 
as GM-CSF, IFNγ, IL8, IL12, IL15, IL18, and IL21 (Vacchelli et al. 
2015, Floros & Tarhini 2015). The results have been modest and 
adverse events severe regarding monotherapies, which is why 
current trials often study cytokines in combination with other 
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immunotherapies, chemotherapy, or radiation therapy (Floros & 
Tarhini 2015). 
1.3.1 INTERFERON BETA 
IFNs were discovered in the 1950s and named after their ability to 
interfere with viruses in infected cells (Razaghi et al. 2016). IFNs fall 
into to three distinct groups: Type I, II, and III. IFNβ belongs to Type 
I IFNs, together with IFNα, IFNε, IFNκ, and IFNω (Zitvogel et al. 
2015). Mainly fibroblasts and plasmacytoid dendritic cells produce 
IFNβ as a response to a virus, lipopolysaccharide, or double-stranded 
RNA (Farrar & Schreiber 1993). 
Like all Type I IFNs, IFNβ binds to the heterodimeric IFNα/β 
receptor consisting of IFNAR1 and IFNAR2 and signals through the 
Jak-Stat pathway (Samuel 2001). Tyk2 and Jak1 interact with IFN 
receptors and phosphorylate Stat2 and Stat1, respectively. Next, 
Stats form a complex with IRF-9, which then acts as a transcription 
activator (Samuel 2001). The main function for all IFNs is to produce 
antiviral proteins and induce antigen presentation, but IFNβ 
uniquely affects, for example, Hypoxia-inducible factor-1 and 
Protein kinase R (Der et al. 1998). On the contrary, IFNβ is a less 
potent inducer of pro-apoptotic genes compared with IFNα and IFNγ 
(Der et al. 1998). Regarding effects on immune cells, Type I IFNs in 
general enhance T-cell and NK-cell cytotoxicity and induce dendritic 
cell maturation and migration (Zitvogel et al. 2015). 
Defects in Type I IFN signalling or production have been 
associated with mammary carcinogenesis (Zitvogel et al. 2015). 
Despite its cell proliferation restricting and immune system 
stimulating functions, IFNβ has not been that promising against 
cancer. Several clinical trials have studied the efficacy of IFNβ in 
combination with standard treatment for glioblastoma, breast 
cancer, pancreatic cancer, and non-small-cell lung cancer (Utsuki et 
al. 2011, Recchia et al. 2009, Colman et al. 2006, Bradley et al. 2002, 
Recchia et al. 1998, Repetto et al. 1996). The results, however, show 
poor effects on survival and tumour growth control, even though the 
rationale behind the treatment is strong: Many conventional 
therapies, such as chemotherapy and radiation therapy, work 
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through Type I IFN induction (Zitvogel et al. 2015). IFNβ is currently 
an approved treatment for multiple sclerosis (Samuel 2001). 
1.3.2 INTERFERON GAMMA 
IFNγ is the only member of Type II IFNs. It is the most active among 
the interferon protein family, being up to 10 000 times stronger an 
immune-modulator than the other IFNs but less specific for antiviral 
activities (Pace et al. 1985). It was discovered in 1965 as a response 
to virus infection, and its structure was resolved with X-ray 
crystallography in 1991 (Ealick et al. 1991, Wheelock 1965). CD8+ T 
cells, Th1 helper cells, and NK cells produce IFNγ when stimulated 
with antigens and mitogens (Farrar & Schreiber 1993). IL12 also 
stimulates the production (Wolf et al. 1991). 
IFNγ appears as a soluble 34-kDa homodimer (Farrar & 
Schreiber 1993). It binds to the heterodimeric IFNγ receptor 
consisting of IFNGR1 and IFNGR2 that are expressed on most cell 
types. Binding of IFNγ to its receptors activate Jak1 and Jak2, which 
phosphorylate Stat1. Stat1 forms a homodimer known as gamma 
activation factor that activates gene expression through GAS 
enhancer element (Samuel 2001). 
All IFNs regulate HLA class I expression on most cells, but IFNγ 
can also induce class II expression on other than B cells, where it 
regulates immunoglobulin production (Samuel 2001, Snapper & 
Paul 1987, Mond et al. 1986). The most noticeable responders for 
IFNγ are monocytes and macrophages in which IFNγ promotes 
expression of nitric oxide synthase that catalyses the production of 
antimicrobial and antiviral nitric oxide (Samuel 2001). IFNγ also 
promotes antigen presentation and interaction between T cells and 
macrophages (Farrar & Schreiber 1993). Regarding other than 
immune cells, IFNγ stimulates cell death in apoptosis-resistant cell 
lines by upregulating caspase 8 (Fulda & Debatin 2002). 
The clinical results against cancer are modest despite the positive 
effects on immune reactions and driving cells to apoptosis (Razaghi 
et al. 2016, Samuel 2001). IFNγ stimulates cytotoxic and helper T 
cells, NK cells, and B cells in non-invasive bladder cancer patients 
(Giannopoulos et al. 2003). In ovarian cancer patients, the addition 
of IFNγ to a standard treatment increases progressive free survival, 
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but the effect on overall responses is questionable (Alberts et al. 
2008, Windbichler et al. 2000). IFNγ has no efficacy against renal 
cell carcinoma or colon cancer (Gleave et al. 1998, Wiesenfeld et al. 
1995). Treatment with recombinant IFNγ causes flu-like symptoms 
and neutropenia as adverse events (Marth et al. 2006, Windbichler 
et al. 2000). 
1.3.3 TUMOUR NECROSIS FACTOR ALPHA 
As the name suggests, Tumour Necrosis Factor alpha (TNFα) first 
appeared as a substance causing tumour cell apoptosis and necrosis, 
but it is currently associated mainly with inflammation (Baud & 
Karin 2001, Carswell et al. 1975). TNFα belongs to a TNF superfamily 
consisting of transmembrane type II proteins with intracellular N-
terminus. TNFα also acts as a trimeric soluble protein when 
proteolytically cleaved by ADAM17 (Black et al. 1997). Both soluble 
and transmembrane forms are active and mainly produced by 
activated macrophages, monocytes, lymphocytes, keratinocytes, and 
fibroblasts (Baud & Karin 2001).  The crystal structure of the trimer 
was described in 1989; it consists of monomers 17 kDa in size (Eck & 
Sprang 1989).  
TNFα signals through two members of the TNF receptor (TNFR) 
superfamily, TNFR1 and TNFR2. TNFR1 is present on most cell 
types, whereas TNFR2 is mainly on immune cells and endothelial 
cells (Brenner et al. 2015). The binding of TNFα to TNFR1 leads to 
the recruitment of TRADD (TNFR-associated death domain) to 
interact with the receptor. TRADD mediates the signalling for 
apoptosis, whereas in the presence of RIP1 or TRAF2/5, the 
signalling leads to proliferation or inflammation via activation of 
MAP kinase or NFκB signalling pathways, respectively (Brenner et 
al. 2015, Baud & Karin 2001). Activation of TNFR2 mostly leads to 
cell survival signalling via NFκB. TNFα also stimulates the 
production of chemokines, cytokines, and growth factors, such as 
CXCL9, CXCL10, CCL17, IL1α, IL8, GM-CSF, and TGFα (Liu et al. 
2007, Janes et al. 2006, Balkwill 2006, Tessier et al. 1997).  The 
outcome of the signalling depends on the presence of intracellular 
mediators and other cytokines and growth factors (Janes et al. 2006, 
Pimentel-Muinos & Seed 1999). 
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TNFα has a conflicting role as causing not only cancer-driving 
chronic inflammation but also tumour cell necrosis (Balkwill 2006). 
Because of its cancer-promoting features, trials have been conducted 
with anti-TNFα antibody. These treatments, however, might also 
increase cancer risk (Askling et al. 2011). Historically, TNFα appears 
to be an active component of Coley’s toxin, William Coley’s 
experimental treatment for cancer patients in the late 19th (Bickels et 
al. 2002). Recombinant TNFα was studied in the 1980s as a systemic 
treatment in clinical trials, but the major problems occurred with 
dose-limiting toxicities and lower doses led to modest responses 
(Wiedenmann et al. 1989). Low doses, however, induce positive 
changes in the activation status of patient PBMCs, indicating that 
TNFα might have an important role in inducing system-wide 
immune reactions against tumours (Logan et al. 1997). Intralesional 
application is safer than systemic, but the responses remain local 
(Bartsch et al. 1989). 
Recombinant TNFα was later studied in an isolated limb 
perfusion setting for regional treatment of sarcomas and 
melanomas. Positive results led to the approval of TNFα for clinical 
use in 1998 (van Horssen et al. 2006). The overall response rates for 
limb perfusions are impressive: 76% for sarcomas and up to 100% 
for melanomas. Of melanoma patients, complete responders 
comprise over 70% (van Horssen et al. 2006). The mechanism 
behind antitumour efficacy lies in induced tumour necrosis, early 
infiltration of lymphocytes and macrophages, and in hampering the 
tumour metabolism by affecting its vasculature (van Horssen et al. 
2006, Lejeune et al. 1998). The treatment, however, may cause 
severe adverse events, such as hypotension with tachycardia and 
kidney failure (Lienard et al. 1992). Improved safety of systemic 
delivery was achievable lately with modified TNFα and vectored 
delivery with even higher antitumour efficacy (Li et al. 2012, Li et al. 
2010, McLoughlin et al. 2005).  
1.3.4 INTERLEUKIN 2 
First nominated as T-cell growth factor, IL2 is a strong stimulator for 
T-cell propagation and differentiation. The crystal structure of this 
15 kDa monomeric glycoprotein was published in 1992 (Bazan 1992). 
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IL2 belongs to the Type I cytokine family, and it is secreted mainly 
by CD4+ and CD8+ T cells but also by B cells and dendritic cells to a 
lesser extent (Gaffen & Liu 2004). Binding of an antigen to its 
receptor in effector T cells rapidly initiates the synthesis of IL2, thus 
creating a positive loop for activated T-cell expansion (Lenardo et al. 
1999).   
IL2 affects cells by binding to a trimeric receptor complex 
consisting of IL2 receptor alpha, beta, and gamma (Gaffen & Liu 
2004). At least the two latter components are necessary for signalling 
pathway activation (Nelson et al. 1994). The signalling cascade starts 
with tyrosine kinases Jak1 and Jak3, which leads to activation of 
transcription factor Stat5 or further signalling via MAPK or PI-3K 
pathways (Malek & Castro 2010).  
The signalling cascade influences lymphocyte proliferation via c-
Myc and c-Fos, in addition to inhibiting apoptosis via Bcl-2 
(Miyazaki et al. 1995). Importantly, IL2 also controls immune 
reactions via a negative feedback loop by inducing the expression of 
pro-apoptotic FasL, thus preventing autoimmunity (Refaeli et al. 
1998). Moreover, the half-life of recombinant IL2 in humans is only 
minutes (Lotze et al. 1985). In addition to T cells, IL2 stimulates B 
and NK cells (Gaffen & Liu 2004). 
The FDA approved the use of recombinant IL2 as a treatment for 
metastatic melanoma and renal cell cancer in 1998. The overall 
response rate for melanoma patients, however, is only 16%, and the 
proportion of complete responders is 6% (Atkins et al. 1999). The 
overall objective response rate for patients with metastatic renal cell 
cancer is 20%, and 9% result in complete response (Klapper et al. 
2008). Treatment with recombinant IL2 correlates with enhanced 
tumour infiltration of CD4+ and CD8+ T cells and macrophages 
(Rubin et al. 1989). A major downside of IL2, however, is induction 
of immunosuppressive Tregs (Ahmadzadeh & Rosenberg 2006). 
In addition to low response rates, treatment with high doses often 
correlates with severe adverse events, such as cytokine release 
syndrome and vascular leak syndrome, leading to liver cell damage 
and renal failure (Panelli et al. 2004, Rosenberg et al. 1994, 
Rosenberg et al. 1987, Lotze et al. 1985). At worst, high-dose IL2 has 
caused mortality in 4% of the patients (Schwartz et al. 2002). 
Lowering the dose diminishes adverse events with a cost in efficacy 
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(Yang et al. 2003). Fortunately, the toxicities are transient in most 
cases (Atkins et al. 1999).  
Histological evaluation of renal cancer patients before treatment 
can improve the response rate from 27% up to 52%, lowering the 
risk-to-benefit ratio (Shablak et al. 2011). Local administration also 
appears more efficient and safer than systemic delivery (Ray et al. 
2016, Weide et al. 2011). Several genetically engineered variants of 
IL2 and fusion proteins are under development to maximize efficacy 
and to minimize adverse effects and Treg stimulation (Rosalia et al. 
2014). Moreover, in vivo results and phase I clinical trials suggest 
that vectored delivery of IL2 is safer and more efficient than the 
administration of recombinant protein (Dummer et al. 2008, Trudel 
et al. 2003, Slos et al. 2001). 
1.4 ONCOLYTIC VIRUSES IN IMMUNOTHERAPY 
Oncolytic viruses selectively replicate only in cancer cells. The lytic 
effect self-amplifies at the tumour while normal cells remain intact 
(Chiocca & Rabkin 2014). Genetic modifications enable oncolytic 
viruses to take advantage of the abnormal functions of malignant 
cells, but some viruses have this character by nature. Natural 
oncolytic viruses include parvoviruses, myxoma virus, Newcastle 
disease virus, reovirus, Seneca Valley virus, and coxsackievirus 
(Dharmadhikari et al. 2015, Chiocca & Rabkin 2014). Measles virus, 
poliovirus, vaccinia virus, herpes simplex virus, vesicular stomatitis 
virus, and adenovirus can also be made cancer selective by genetic 
engineering (Chiocca & Rabkin 2014).  
Currently, there are 69 oncolytic viruses in clinical trials and 95 
in the preclinical stage (Tang et al. 2018). An unarmed oncolytic 
adenovirus, H101 by Sanghai Sunwaybio, was approved for treating 
nasopharyngeal cancer in China in 2005, and oncolytic herpes 
simplex virus by Amgen coding for GM-CSF, T-Vec, was approved 
ten years later in the USA and Europe (Grigg et al. 2016, Garber 
2006). A phase III clinical trial with a combination of H101 and 
chemotherapy resulted in a 79% response rate, improving 
chemotherapy alone by 39 percentage units (Garber 2006). T-Vec 
yields an objective response rate of 26.4%, comprising complete 
responders (10.8%) and partial responders (15.6%) (Andtbacka et al. 
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2015). Other oncolytic viruses in phase III trials include an 
adenovirus coding for thymidine kinase (ProstAtak by Advantagene) 
and an adenovirus coding for GM-CSF (CG0070 by Cold Genesys) 
(Kaufman et al. 2015). Several other adenoviruses, herpesviruses, 
reovirus, Seneca Valley virus and coxsackievirus are also in phase II 
trials (Kaufman et al. 2015). 
The responses to oncolytic viruses derive both from direct cancer 
cell lysis and from immune reactions (Figure 3). Oncolytic viruses 
induce immunogenic cell death, which is a stronger activator for 
antitumour immunity than apoptotic cell death (Inoue & Tani 2014, 
Kepp et al. 2009). The immunogenic cell death releases pathogen- 
and danger-associated molecular patterns into the tumour 
microenvironment, which helps the immune system to recognize the 
infected cancer cells (Tang et al. 2012). Moreover, infection enhances 
the release of tumour-associated antigens, novel cancer antigens 
(neo-antigens), and epitope spreading, which also enable immune 
reactions against uninfected cells (Kaufman et al. 2015, Chiocca & 
Rabkin 2014).  
 
Figure 3. Oncolytic virus-mediated antitumour mechanisms. Infected tumour cell 
alerts immune system when expressing danger- and pathogen-associated molecular 
patterns. When the virus exits the cell, tumour-associated antigens are released to the 
tumour microenvironment, and the infection spreads to the neighbouring cells. Figure 
is constructed according to Kaufman et al. 2015. 
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The main problems with viral vectors are the pre-existing or 
emerging antivirus antibodies, tumour unavailability because of 
poor vasculature, and the virus spreading to unwanted organs 
(Chiocca & Rabkin 2014). Inside the tumour, hypoxia might restrict 
virus replication and a dense matrix prevents the virus from 
spreading (Mok et al. 2007, Shen & Hermiston 2005). Pre-existing 
neutralizing antibodies and circulating complement regulatory 
proteins hinder the virus delivery or persistence in a tumour (Biswas 
et al. 2012, Tomita et al. 2012). However, antiviral immune 
responses – even pre-existing – seem also to enhance antitumour 
immunity (Ricca et al. 2018, Li et al. 2017). In addition, cancer cells 
often overexpress proteins that viruses can use as receptors 
(Kaufman et al. 2015). For example, coxsackie-adenovirus receptor 
(CAR) is downregulated in many cancers, but adenovirus type 3 
receptor desmoglein-2 is more commonly expressed in tumours 
(Biedermann et al. 2005, Sachs et al. 2002, Harada et al. 1996). 
1.4.1 ADENOVIRUSES 
Every fifth clinical trial focusing on gene therapy involves 
adenovirus, making it currently the most common virus vector 
(Edelstein 2017). The Adeneviridae family belonging to the 
Mastadenovirus genus comprises seven human adenovirus species 
(nominated alphabetically from A to G) and several animal 
adenovirus species (Hoeben & Uil 2013). Currently, different human 
adenovirus species include over 50 types or serotypes (Hoeben & Uil 
2013, Nemerow et al. 2009). 
1.4.1.1 Adenovirus life cycle 
Adenovirus has a linear, circa 36 000 base pairs (bp) long, double-
stranded DNA genome (Hoeben & Uil 2013). The naked icosahedral 
capsid is 70 to 90 nm in diameter. Trimeric hexons form the capsid 
with pentons at each vertex. Each penton holds a knobbed fibre 
protruding from the middle (Nemerow et al. 2009). The virus 
attaches to cells usually via a fibre knob, which most commonly has 
a high affinity for CAR, a glycoprotein located near tight junctions of 
epithelial cells (Bergelson et al. 1997). In addition, group B and D 
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adenoviruses use CD46 or desmoglein-2 as entry receptors (Wang et 
al. 2011, Wu et al. 2004, Gaggar et al. 2003). 
Penton interaction with αvβ3 or αvβ5 integrin aids the adenovirus 
internalization into clathrin-coated vesicles (Wickham et al. 1993). 
The virus escapes from the early endosome and travels towards the 
nucleus along microtubules, gradually degrading the capsid 
structure (Figure 4) (Leopold et al. 1998, Greber et al. 1993). The 
viral DNA enters the nucleus and interacts with host-cell histones 
(Giberson et al. 2012). 
 
Figure 4. Adenovirus life cycle. Adenovirus enters a cell in clathrin-coated vesicles 
following attachment to CAR (1). The lowering pH inside an endosome starts disrupting 
the virus capsid and releases the virus into cytosol. The capsid delivers DNA into the 
nucleus, where the production of new virus particles starts with the transcription of early 
genes (2). Structural proteins accumulate in the cytosol (3), but the assembly occurs 
inside the nucleus (4). Upon exit, adenovirus disrupts the cell, releasing up to 10 000 
new virus particles into the surroundings (5). Figure is constructed according to 
Giberson et al. 2012. 
Adenovirus genome comprises one immediate-early unit (E1A), four 
early gene regions (E1B, E2, E3, and E4), and five late gene regions 
(L1 to L5). The early gene products prepare the cell for virus DNA 
replication. Only E2 is necessary for the DNA replication, which 
occurs before starting the late gene transcription. The late genes 
mainly encode structural proteins from splice variants of a single 
transcript (Giberson et al. 2012). 
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After genome replication and translation, adenovirus assembly 
occurs sequentially: Hexons and pentons form empty capsids with 
non-structural proteins in the first phase. Next, a viral genome 
associates with packaging proteins and enters the capsids. Finally, a 
viral protease cleaves immature precursor proteins, enabling virus 
particle maturation (Ahi & Mittal 2016). The adenovirus replication 
cycle takes 24 to 36 hours, after which over 10 000 virions lyse the 
cell and escape (Giberson et al. 2012). 
Adenovirus infections are common worldwide throughout the 
year. It can spread via direct contact, droplet transmission, or faecal-
oral route with food and water as possible vectors (Echavarria 2008). 
The infection may remain asymptomatic, but it generally causes mild 
respiratory tract infection and symptoms like fever, eye 
inflammation, or diarrhea (Echavarria 2008). Latent adenoviruses, 
especially of species C types 1, 2, and 5, often persist in tonsils 
(Garnett et al. 2007). The virus is also able to remain stable outside 
a host for several weeks (Echavarria 2008).  
1.4.1.2 Modifications 
Because adenoviruses are not oncolytic by nature, modifications 
restricting infection and replication to cancer cells are necessary 
(Dharmadhikari et al. 2015). One of the most crucial adenovirus 
proteins regarding initiation of replication is E1A (Radko et al. 2015). 
Adding a cancer-specific promoter prior to this gene takes advantage 
of proteins commonly overexpressed in certain cancer types. For 
example, oncolytic adenovirus CV706 has E1A under prostate-
specific antigen promoter and has showed efficacy in prostate cancer 
patients in a phase I trial (DeWeese et al. 2001). More commonly 
overexpressed in various cancer types is hTERT (human telomerase 
reverse transcriptase), which has been utilized, for example, in 
adenovirus KH901 where hTERT promoter regulates E1A (Chang et 
al. 2009).  
E1A drives the host cell to S-phase and enables adenovirus 
replication by interfering with the retinoblastoma (Rb) signalling 
pathway (Whyte et al. 1988). The Rb pathway is commonly disabled 
in cancer cells, leading to excess E2F expression, which allows 
adenovirus to replicate in cancer cells without E1A binding Rb (Heise 
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et al. 2000). This appears as a safety mechanism in many adenovirus 
designs: 24-bp disabling deletion of E1A restricts adenovirus 
replication to cancer cells and prevents replication in non-replicating 
normal cells (Figure 5) (Heise et al. 2000). In addition, 
incorporation of E2F promoter before E1A improves the selectivity 
further (Rojas et al. 2009). 
 
Figure 5. Selective replication of oncolytic adenovirus bearing 24-bp deletion at 
E1A. Wild type adenovirus E1A binds to cellular retinoblastoma protein, enabling 
accumulation of free E2F, which drives the cell to S-phase (A). Deletion of 24 bp at the 
region binding to retinoblastoma prevents virus replication in normal cells (B), whereas 
in cancer cells, the defects in the retinoblastoma pathway do not affect virus replication 
(C). Figure is constructed according to Heise et al. 2000. 
One of the most common mutations in cancer cells, in addition to the 
Rb pathway, relates to apoptosis-inducing protein p53. Adenovirus 
protein E1B inhibits host cell apoptosis by binding and inactivating 
p53. A deletion in this gene region makes infected normal cells 
susceptible to apoptosis, whereas cancer cells are more prone to virus 
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infection and replication (Cheng et al. 2015). For example, the first 
published, conditionally replicating oncolytic adenovirus, ONYX-
015, and the approved H101, rely on deletion in E1B 55K as a 
selection mechanism (Cheng et al. 2015, Heise et al. 1997). 
1.4.2 ONCOLYTIC VIRUSES AS VECTORS 
Modifications for selective replication direct the replication and 
immunological effects to tumours, but the addition of a transgene, 
such as a cytokine, usually enhances the efficacy (Liu et al. 2012). 
Moreover, because a high dosage of recombinant cytokines 
commonly induces severe adverse events, vectored delivery has also 
become of interest from a safety perspective (Kaufman et al. 2015). 
Herpes simplex virus and vaccinia virus can carry the largest 
transgenes, but adenoviruses can also accommodate several 
thousand base pairs of extragenomic DNA (Kaufman et al. 2015). 
Currently, one of the most studied transgenes inserted in a virus 
genome is GM-CSF. T-Vec encodes this cytokine and clinical trials 
are ongoing with GM-CSF-armed vaccinia virus and adenovirus 
(Ranki et al. 2016, Breitbach et al. 2015, Andtbacka et al. 2015). In 
addition to GM-CSF, several other cytokines, such as interleukins, 
TNFα, IFNα/β, soluble CD80, CD40L, Flt3L, and some chemokines 
alone or in different combinations, have been investigated as arming 
devices in preclinical and some in clinical studies (Hirvinen et al. 
2015, Kaufman et al. 2015, Chiocca & Rabkin 2014, Liu et al. 2012). 
In addition to arming viruses with cytokines, preclinical data shows 
much promise with modified viruses expressing soluble, tumour-
associated antigens or carrying them on their surfaces (Capasso et al. 
2015, Pulido et al. 2012). Moreover, viruses delivering genes to 
replace malfunctioning genes in target cells, for example, pro-
apoptotic p53 in cancer cells, represent the traditional approach in 
gene therapy (Zhang et al. 2013). 
Oncolytic viruses are an intriguing option for transgene delivery, 
as they enable local transgene expression on tumour sites with 
reduced systemic adverse events (Larocca & Schlom 2011). The virus 
itself simultaneously induces immunological reactions and exposes 
the immune-escaped tumour for destruction by the patient’s own 
immune system.   
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2 AIMS OF THE STUDY 
The aims of this study are 
1. to evaluate the mechanisms behind antitumour efficacy of 
adenovirally delivered IL2 and TNFα combined with 
adoptive cell transfers (I, II); 
2. to evaluate the potential antitumour effects on distant 
tumours with local administration of viruses (III); and 
3. to study if adenovirally delivered IL2 is equal to systemic 
administration of IL2 in terms of improving adoptive cell 
transfers (IV). 
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3 MATERIALS AND METHODS 
3.1 CELL LINES (I–IV) 
All the cell lines originate from ATCC (Manassas, VA, USA) unless 
otherwise stated in Table 1. The cells were cultured in RPMI-1640 
or DMEM supplemented with 10% FBS, 2 mM L-glutamine, 100 
U/ml penicillin, and 100 μg/ml streptomycin (all from Sigma-
Aldrich, St Louis, MO, USA). Table 1 presents the additional 
supplements. The growth conditions for all cell lines were +37°C and 
5% CO2. The cell lines used in animal experiments (B16.OVA, 
SKOV3-Luc, HapT1, and DDT1-MF2) were tested to be pathogen free 
at Surrey Diagnostics Ltd (Granleigh, UK). 
Table 1. Cell lines used in the study. Growth media included 10% FBS, 2 
mM L-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin, unless otherwise 
stated. 
Cell line Origin Growth media Source Study 
Human cell lines 
293 Embryonic 
kidney 
DMEM ATCC I 
A549 Lung 
carcinoma 





20% FBS,  


































































100 μg/ml Normocin 
(Invivogen) 
InvivoGen, 
San Diego, CA, 
USA 
I 




ATCC I, II 
L929 Fibroblasts DMEM ATCC I, II 
3.2 GENERATION OF VIRAL CONSTRUCTS (I–
IV) 
The construction of non-replicating control viruses Ad5-Luc1 and 
Ad5/3-Luc1 has been described by Krasnykh et al. (2001, 1996). 
Adenoviruses coding for murine cytokines were constructed by 
inserting expression cassettes of murine IFNγ, IL2, IFNβ, and TNFα 
into a shuttle plasmid pDC315 (AdMax, Microbix Biosystems, 
Mississauga, Canada). The shuttle plasmids were transfected into 
293 cells together with a plasmid pBHGlox-delE13vre (AdMax) 
containing adenovirus genome with cytomegalovirus (CMV) 
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promoter and deleted E1 and E3 regions. The transgenes were 
introduced under the CMV promoter to replace the deleted E1 region 
by site-specific recombination. The viruses were purified with 
caesium chloride gradient centrifugation (Luo et al. 2007), and the 
yield of viral particles (VP) was determined with spectrophotometer 
by reading at 260 nm wavelength. Spectrophotometer measures the 
amount of DNA in a sample, which is converted to VP titer using an 
artificially determined extinction coefficient (Mittereder et al. 1996). 
Infectious units were calculated according to Tissue Culture 
Infectious Dose (TCID50) assay. 
The oncolytic adenoviruses were generated to a backbone of 
Ad5/3-E2F-d24 bearing fibre knob from adenovirus serotype 3, E2F 
promoter for E1A, a 24-bp deletion at the Rb protein-binding region 
at E1A, and deleted E1B 19K. The expression of the transgenes 
(human IL2 and/or TNFα) was linked to virus replication by 
replacing Gp19k and 6.7K at E3 region with the transgenes. The 
insertion was done using the BAC-recombineering strategy based on 
the selection marker galK (Muck-Hausl et al. 2015, Ruzsics et al. 
2006, Warming et al. 2005). The internal ribosome entry site (IRES) 
between TNFα and IL2 acts as a translation initiation site.  
The oncolytic viruses were produced with A549 cells and purified 
by caesium chloride gradient centrifugation. The critical parts of 
viral genomes (Knob3, d24, and E3) were verified with polymerase 
chain reaction (PCR). Table 2 lists the primer sequences. Ad5/3-
E2F-d24-hTNFα-IRES-hIL2 was additionally sequenced at the 
Biomedicum Functional Genomics Unit (FuGU, Helsinki, Finland). 




Table 2.  Primers used for validating the produced viruses. PCR running 
conditions included initial denaturation at 98°C for 30 s and 30–35 times repeated 
cycles of denaturation at 98°C for 10 s, annealing at 55–57°C for 20 s, and elongation 
at 72°C for 20–60 s. The final elongation step lasted 7 min at 72°C. 
Gene Type Sequence (5’-3’) 
E1A 
Forward primer GTCCGGTTTCTATGCCAA 
Reverse primer TCACCCTCTTCATCCTCGTC 
Knob3 
Forward primer GCACAGGTGCCATTACAGTAG 
Reverse primer TCATTATGTGTTCCCGCATTA 
E3 
Forward primer CCAGACGGAGTGAGTCTACG 
Reverse primer TCGCTGTAGTTGGACTGGAAC 
 
Table 3. List of viruses used in the study. All viruses have a backbone of 
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II, III  
3.3 FUNCTIONALITY OF THE VIRUSES (I AND II) 
The cell-killing ability of oncolytic viruses was determined by 
infecting a panel of cancer cell lines with an increasing viral dose. The 
presence of the cytokines coded by the transgenes was measured 
from cell culture growth media supernatants after infection. In 
addition, the indicator cell lines proved the biological activity of the 
cytokines. 
3.3.1 MTS CELL PROLIFERATION ASSAY (II) 
A panel of human (A549, SKOV3-Luc, OVCAR-3, Panc1, and SK-
MEL-28) and hamster (HapT1 and DDT1-MF2) cancer cell lines were 
infected with 1–1 000 VP/cell or 1-10 000 VP/cell, respectively, in 
Study II. The cells were incubated with the viruses for 3–7 days until 
visible cell killing was achieved with the highest dose. Replication-
incompetent Ad5/3-Luc1 virus served as a negative control. 
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Viable cells were detected with 10% MTS solution [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium; CellTiter 96 AQueous One Solution, 
Promega, Madison, WI, USA] after a two-hour incubation. In the 
assay, metabolically active cells reduce the MTS reagent, generating 
a coloured, soluble formazan product. The amount of the product is 
relative to the amount of viable cells and is detectable with 
spectrophotometer at the wavelength of 490 nm. 
3.3.2 CYTOKINE EXPRESSION (I AND II) 
Murine cytokines were detected in Study I from virus-infected (100 
VP/cell) 293 cell growth media supernatants 48 hours after 
infection. The supernatants were filtered through a 0.02 μm filter 
(Whatman, GE Healthcare Life Sciences, Chicago, IL, USA) to 
eradicate the viruses. The following enzyme-linked immunosorbent 
assays (ELISA) were used according to the manufacturer’s protocol: 
mIFNβ (PBL InterferonSource, Piscataway, NJ, USA), mIFNγ 
(Abcam, Cambridge, UK), mIL2, and mTNFα (IBL International, 
Hamburg, Germany). 
For human cytokine detection in Study II, two human (A549 and 
SKOV3-Luc) and hamster (HapT1 and DDT1-MF2) cancer cell lines 
were infected with 1 000 VP/cell and 5 000 VP/cell, respectively. The 
cell supernatant was collected 72 hours after infection and filtered 
through a 100-kDa filter unit (Amicon Ultra 4, Merk Millipore, 
Billerica, MA, USA). The cytokine concentrations of the diluted 
supernatants were determined with BD Cytometric Bead Array 
(CBA) Human Soluble Protein Master Buffer Kit together with 
Human IL2 and TNFα Felx Set kits (BD, Franklin Lakes, NJ, USA) 
according to the manufacturer’s instructions. 
Replication-incompetent viruses with murine cytokines were 
injected into subcutaneous B16.OVA tumours (1 x 109 VP) in 
C57BL/6 mice (Envigo, Cambridgeshire, UK) to measure whether 
the cytokines were also produced in vivo in Study I. In Study II, 
oncolytic viruses were injected into subcutaneous HapT1 tumours (1 
x 108 VP) established in Golden Syrian hamsters (Mesocricetus 
auratus, Harlan laboratories/Envigo). The tumours and the blood 
were collected 72 hours after infection. Tumours were snap-frozen 
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and stored at -80°C before homogenization. The blood was 
incubated for one hour at room temperature before high-speed 
centrifugation to separate the serum from the red blood cells. The 
cytokine concentrations were measured with CBA and normalized to 
the total protein content of the sample. 
3.3.3 BIOLOGICAL ACTIVITY OF THE CYTOKINES (I AND II) 
The biological activity of the cytokines was investigated with 
indicator cell lines in Studies I and II. B16-Blue IFN-α/β murine type 
I IFNs sensor cells were used to evaluate the functionality of mIFNβ 
present in the cell culture supernatant according to the 
manufacturer´s instructions. The binding of mIFNβ to the receptors 
on these cells triggers the production of SEAP, which can be 
monitored using a specific detection medium. 
The functionality of mIFNγ was determined by its ability to 
protect L929 cells from vesicular stomatitis virus (VSV) infection. 
The cells were seeded on a 96-well plate (3.5 x 104 cells/well) and 
incubated for six hours with the supernatants. The supernatant was 
then removed and the cells infected with VSV strain M51 (from Dr. 
Markus Vähä-Koskela, University of Helsinki) 1 x 104 VP/well. Cell 
viability was determined 96 hours later with MTS assay. 
The L929 cells are sensitive for both human and murine TNFα in 
the presence of actinomycin D. The cell supernatants and 
actinomycin D (2 μg/ml) were added to the cells and incubated for 
24 hours before measuring the cell viability. 
Functionality of human and murine IL2 was determined by 
measuring the viability of CTLL-2 lymphocytes (5 x 104 cells per well 
on a 96-well plate) after a 72-hour incubation with the cell 
supernatants. Commercial cytokine products were used as positive 
controls in all functionality assays: 1 ng/ml of mTNFα, mIL2, and 
mIFNγ; 1000 IU/ml mIFNβ; 0.5 ng/ml hTNFα; and 10 ng/ml hIL2 
(all from R&D Systems, Minneapolis, MN, USA). 
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3.4 ANIMAL EXPERIMENTS (I–IV) 
All animal protocols were reviewed and approved by the 
Experimental Animal Committee of the University of Helsinki and 
the Provincial Government of Southern Finland. In addition, the 
National Animal Experiment Board (Eläinkoelautakunta ELLA) of 
the Regional State Administrative Agency of Southern Finland 
granted permission for the experiments 
(ESAVI/7759/04.10.07/2013 and ESAVI/7755/04.10.07/2016). The 
animals were quarantined for at least a week before starting the 
experiments. All injections were given to animals anesthetised with 
isoflurane. The health status of the animals was monitored daily and 
the animals were sacrificed upon visible distress, tumour ulceration, 
or when the tumour diameter reached 18 mm or 22 mm for mice and 
hamsters, respectively. 
3.4.1 IMMUNOCOMPETENT MICE (I, III, AND IV) 
Mouse melanoma B16 tumours expressing chicken ovalbumin (OVA) 
were established subcutaneously with 2.5 x 105 cells to C57BL/6 mice 
(Envigo) in Studies I, III, and IV. The mice were randomized into 
groups of 5–11 when the average tumour diameter reached 
approximately 5 mm after 10 days. Tumour size was followed with a 
digital caliper and the volume estimated with a formula: o.52 x (max 
dimension) x (min dimension)2. 
The tumours in Study I were treated with 1 x 109 VP (Ad5-CMV-
mIFNβ, Ad5-CMV-mIFNγ, Ad5-CMV-mIL2, or Ad5-CMV-mTNFα) 
in 50 μl PBS with or without systemic administration of 1.5 x 106 
CD8-enriched OVA-specific OT-I cells (described later) in 100 μl of 
plain RPMI-1640. The virus treatments were repeated every seven 
days and the tumour growth was followed with digital caliper every 
two to three days (Figure 6). 
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Figure 6. Schedule and treatment groups for mouse experiment studying the 
efficacy of cytokine-armed adenoviruses. The viruses were administered alone or 
together with OVA-specific OT-I T cells to animals bearing B16-OVA melanoma 
tumours. 
Two viruses with the best efficacy (Ad5-CMV-mIL2 and Ad5-CMV-
mTNFα) were combined to achieve a superior antitumour efficacy 
and induction of T-cell transfer. Equal amounts of viruses (0.5 x 109 
VP per virus) were administered intratumourally once a week with 
or without a single treatment with OT-I cells (Figure 6). Tumour 
growth was followed as in the first experiment. 
Two B16.OVA tumours were implanted on the flanks of C57BL/6 
mice to assess the effects of a local treatment with armed 
adenoviruses on distant tumour growth in Study III (Figure 7). The 
animals received 1.4 x 106 OT-I cells intraperitoneally and a virus 
treatment with Ad5-CMV-mIL2, Ad5-CMV-mTNFα, or both, as 
previously described, only into one tumour. The tumours were 
collected seven days after the treatment, and the immune cell 




Figure 7. Schedule and treatment groups for mouse experiment studying the 
systemic antitumor efficacy of locally administered adenoviruses. Two B16-OVA 
melanoma tumours were engrafted subcutaneously and only one of them treated with 
viruses. 
Local IL2 delivery within a virus genome was compared with 
systemic delivery of recombinant protein in Study IV. The animals 
received daily 1 x 105 IU of murine recombinant IL2 (PeproTech) 
intraperitoneally during 12 days with two days’ rest in the middle of 
the treatment period (Figure 8). The virus group received 1 x 109 VP 
of Ad5-CMV-mIL2 on days 1 and 8. On day 2, 1 x 106 OT-I cells were 
administered for the animals intraperitoneally except for the mock 
control group. On day 13, 24 hours after the last recombinant protein 
treatment, the animals were sacrificed, and samples from tumours, 
bloods, hearts, lungs, livers, spleens, and kidneys were collected to 




Figure 8. Schedule and treatment groups for mouse experiment comparing 
systemic administration of recombinant IL2 with locally administered 
adenoviruses. The mice bearing B16-OVA melanoma received adenovirus coding for 
IL2 locally once a week and recombinant IL2 daily during ten days in total with two-day 
resting period in the middle of the experiment. 
3.4.1.1 Extraction of OVA-specific OT-I T cells (I, III and IV) 
Spleens and inguinal lymph nodes from TCR-transgenic OT-I mice 
(strain C57BL/6-Tg(TcraTcrb)1100Mjb/J, The Jackson Laboratory, 
Bar Harbor, ME, USA) were collected to obtain OVA-specific CD8-
positive T cells for Studies I, III, and IV. The organs were pressed 
through a 70 μm filter and the red blood cells lysed from splenocytes 
with Ammonium-Chloride-Potassium (ACK) buffer (150 mM 
NH4Cl, 10 mM KHCO3, and 110 mM Na2-EDTA). The remaining 
cells were washed twice by suspending the cells to RPMI-1640 
growth media and centrifuging them at the speed of 500xg for four 
minutes. The immune cells were pooled and let settle in RPMI-1640 
media supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml 
penicillin, 100 μg/ml streptomycin, 15 mM HEPES (Sigma-Aldrich), 
50 μM 2-mercaptoethanol (Sigma-Aldrich), and 1 mM Na-pyruvate 
(Sigma-Aldrich). The CD8a positive cells were enriched after 48 
hours using CD8a+ T Cell Isolation Kit II (Miltenyi Biotec, Bergisch 
Gladbach, Germany), following the manufacturer’s protocol. 
Enriched T cells were expanded in the presence of 160 ng/ml 
recombinant murine IL2 (R&D Systems), and 300 ng/ml soluble 
anti-mouse CD3e antibody clone 145-2C11 (Abcam, Cambridge, UK) 




3.4.2 SEVERE COMBINED IMMUNODEFICIENT MICE (II) 
The functionality of the oncolytic viruses was evaluated in Study II 
with female CB-17/Icr-Prkdcscid/Rj mice (Janvier Labs, Saint 
Berthevin, France), aged 4—6 weeks upon arrival,  bearing firefly 
luciferase-expressing otrhotopic ovarian carcinoma SKOV3-Luc. The 
cells (5 x 106) were injected intreperitoneally in 300 μl plain DMEM. 
The animals were randomized into groups three days later and 
treated weekly with intraperitoneal injections. 
To establish an effective dose, the mice were split into groups of 
three receiving 1 x 105, 1 x 107, or 1 x 109 VP of Ad5/3-E2F-d24-TNFα-
IRES-IL2 weekly in 300 μl of phosphate-buffered saline (PBS), or 
PBS only as a vehicle control (Figure 9). Tumour growth was 
followed once a week by imaging the animals with IVIS 100 
(Xenogen, Alameda, CA). Eight minutes before imaging, the animals 
received 3 mg D-luciferin (Synchem, Felsberg, Germany) in 100 μl 
PBS administered to intraperitoneal cavity. D-luciferin is a substrate 
for luciferase initiating the bioluminescent reaction, which can be 
detected with a CCD camera. Bioluminescent imaging was 
performed with the following settings: 10 s exposure time, 1f/stop, 
medium binning and open filter. Photographic images were obtained 
using automatic exposure, 8 f/stop, small binning, and open filter. 
Photographic and bioluminescent images were overlaid with Living 
Image 3.2 (Xenogen) and total flux (photons/s) was measured from 
regions of interest bordering the peritoneal area. 
To investigate whether the transgenes affect the infectivity of the 
viruses, the mice were randomized into groups of 5–7 and treated 
with the dose established in the dose-escalation experiment (1 x 109 
VP, Figure 9). The virus was delivered once a week in 300 μl PBS. 
The vehicle control group received PBS alone. Imaging was 
performed twice a week for three weeks as previously described. 
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Figure 9. Schedule and treatment groups for experiment with immunocompetent 
mice. When investigating the effect of dosing, the animals bearing orthotopic ovarian 
cancer SCOV3-Luc received 105, 107, or 109 VPs once a week, and the experiment 
was stopped on day 18. When comparing the oncolytic activity of the unarmed and 
armed viruses, 109 VPs were administered to the animals weekly until day 21. The 
animals were imaged twice a week. 
3.4.3 GOLDEN SYRIAN HAMSTERS (MESOCRICETUS 
AURATUS) (II–IV)  
Golden Syrian hamsters (Mesocricetus auratus, Harlan 
Laboratories/Envigo) are semipermissive for human adenovirus 
infection unlike mice (Thomas et al. 2006), which makes them a 
useful model to investigate human oncolytic adenoviruses. 
Moreover, some of human cytokines are active in hamsters, 
including IL2 and TNFα. Subcutaneous tumours were established in 
Studies II–IV with 4 x 106 HapT1 cells to 5–6-week-old hamsters, 
and the tumour growth was followed with a digital caliper. The 
animals were randomized into groups of 5–7. 
In Study II, the hamsters were treated intratumourally with 1 x 
109 VP in 50 μl PBS or PBS alone. The animals received virus 
injections on days 1, 4, 8, 13, and 19 (Figure 10A). On day 2, 
tumours received 4 x 105 HapT1 TILs (extraction described later) in 
50 μl of plain RPMI-1640, or media only. The tumour growth was 
followed every two to three days with a digital caliper until day 25, 
when the tumours and relevant organs (heart, lung, liver, spleen, 
kidney, and tumour-draining lymph node) were collected. The 
samples were used for histopathological evaluations and for the 
detection of immune cell subsets. The experiment was repeated with 
the critical virus (Ad5/3-E2F-d24-hTNFα-IRES-hIL2) using 





Figure 10. Schedule and treatment groups for hamster experiments investigating 
the efficacy of oncolytic adenoviruses. The viruses were administered with or 
without TILs that were previously extracted and expanded from the same HapT1 
tumour type. A) The 1*109 VPs were administered to the animals five days in total. B) 
The experiment was repeated with reduced virus dose of 1*108 VPs administered twice. 
Cured animals had a two-week rest period before predisposing them 
for rechallenge. The same tumour cells (HapT1) or immunologically 
distinct (DDT1-MF2) cells were implanted on the flanks of the 
animals (4 x 106 cells/tumour). DDT1-MF2 control tumours reached 
the maximum tolerated diameter (22 mm) 18 days after 
implantation. 
Systemic effects of the local treatment in Study III were evaluated 
by implanting two subcutaneous HapT1 tumours on the flanks of the 
hamsters and treating only one tumour with 1 x 108 VP once a week, 
five treatments in total (Figure 11). In addition, the animals 
received 5 x 107 TILs intraperitoneally in the beginning of the 
treatments. As a control, one group received PBS on the other 
tumour in addition to TILs, and one group was left untreated. Four 
animals per group were sacrificed on day 16 and the tumour sizes in 
the rest 5–6 animals per group were followed until they reached the 
maximum tolerated size (combined maximum dimension of 40 mm). 
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Figure 11. Schedule and treatment groups for hamster experiment studying the 
systemic antitumor efficacy of locally administered oncolytic adenoviruses. Two 
pancreatic HapT1 tumours were engrafted subcutaneously and only one of them 
treated with viruses. Samples for RNA sequencing were collected on day 10 and for 
virus biodistribution on day 16. The tumour growth on rest of the animals was followed 
until humane endpoint criteria were met. 
Four subcutaneous HapT1 tumours were engrafted on hamster 
flanks to evaluate the mechanism behind systemic efficacy in non-
injected tumours on gene-expression level. The animals received TIL 
treatment as previously described and 1 x 108 VP of Ad5/3-E2F-d24-
hTNFα-IRES-hIL2 or the unarmed control virus Ad5/3-E2F-d24 on 
days 1 and 8 into two out of four tumours (Figure 11). A mock 
control group and a group treated only with TILs received PBS 
instead of viruses. Tumours were collected two days after the last 
virus treatment and stored in RNAlater (Life Technologies, Thermo 
Fisher Scientific, Waltham, MA, USA). RNA was extracted with an 
RNeasy Mini Kit (Qiagen, Valencia, CA, USA) following the 
manufacturer’s protocol. The gene-expression levels were evaluated 
by sequencing the messenger RNAs from the samples (described 
later).  
Local delivery of IL2 within an oncolytic virus genome was 
compared with systemic delivery of the recombinant protein in Study 
IV. The hamsters with two established subcutaneous HapT1 tumours 
were treated for three weeks with 5 x 105 IU of animal-free 
recombinant human IL2 (PeproTech) in a series of five days with two 
days recovery period in between the treatment periods (Figure 12). 
Alternatively, the animals received once a week oncolytic Ad5/3-
E2F-d24-hIL2. Additionally, 24 hours after the first treatment with 
the recombinant protein or the virus, 4 x 106 TILs were injected into 
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the tumours. The control groups received intratumoural PBS 
injections with or without TIL treatment. The animals were 
sacrificed 24 hours after the last recombinant protein treatment and 
tumours, bloods, hearts, lungs, livers, kidneys, and spleens were 
collected to evaluate the toxic effects of the treatments, in addition to 
immune cell contents of the tumours. Tumour samples were 
collected also on day 5 from untreated animals or animals treated 
with Ad5/3-E2F-d24 or Ad5/3-E2F-d24-hIL2 to evaluate the effect 
of the treatment on endogenous hamster IL2 production with reverse 
transcriptase quantitative PCR (qPCR). 
 
Figure 12. Schedule and treatment groups for hamster experiment comparing 
systemic administration of recombinant IL2 with locally administered 
adenoviruses. Hamsters bearing two HapT1 pancreatic tumours received oncolytic 
adenovirus coding for human IL2 into both tumours once a week. Recombinant IL2 
was administered systemically on five consecutive days followed by a pause for two 
days. The treatments continued for three weeks. Endogenous IL2 expression was 
examined from samples collected on day 5. Toxicity of the treatment and immune cell 
compartments in tumours were investigated with day 20 samples. 
3.4.3.1 Extraction of TILs (II–IV) 
HapT1 tumours grown for ten days were collected and cut to 
fragments of 1–3 mm3 in size. The fragments were placed into a G-
Rex 10 lymphocyte growth chamber (Wilson Wolf, New Brighton, 
MN, USA), 10-15 fragments per chamber, in RPMI-1640 media 
supplemented with 20% fetal bovine serum (FBS), 2 mM L-
glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, 15 mM 
HEPES, 50 μM 2-mercaptoethanol, 1 mM Na-pyruvate, and 
3000 IU/ml human IL2 (PeproTech, NJ, USA). Half of the media (15 
ml) was changed after five days and every two days after that. 
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Concanavalin A (Sigma-Aldrich, MO, USA) was added with the fresh 
media to yield the concentration of 0.5 ug/ml. The cells were 
collected after ten days in culture and used for the experiments in 
Studies II, III, and IV. 
3.4.4 CELL GRAFT TRAFFICKING (I AND III) 
OVA-specific CD8a+ T cells and the TILs from HapT1 tumours were 
obtained as previously described. The cell grafts were labelled with 
111In-oxine (half-life of 68 h) for 15 min in room temperature and 
washed twice with saline. The mice (n=3/group) received 6 x 106 OT-
I cells (5.98 ± 0.53 MBq per animal) intraperitoneally and 1 x 109 VP 
of Ad5-CMV-mIL2, Ad5-CMV-mTNFα, or a combination of both into 
B16.OVA tumours (Figure 13A). The control group received PBS. 
During days 1, 2, and 4 after the treatments, computed tomography 
images were obtained together with single-photon, emission-
computed tomography images (nanoSPECT/CT, Bioscan Inc., USA). 
The hamsters (n=4/group) received 5 x 107 cells intraperitoneally 
(5.82 ± 0.73 MBq) and 1 x 108 VP of Ad5/3-E2F-d24 or Ad5/3-E2F-
d24-hTNFα-IRES-hIL2 into one of the two HapT1 tumours on day 0 
(Figure 13B). The control group received PBS. The animals were 
imaged on days 2, 3, and 4. The images were aligned with HiSPECT 
NG software (Scivis GmbG, Göttingen, Germany) and analysed with 
InVivo Scope image analysis software (Bioscan Inc., USA). The 
percentage of radioactivity in the tumours was determined by 
dividing the injected dose by the tumour volume (mm3). 
To obtain complementary data on T-cell trafficking into injected 
and non-injected tumours from mice, OT-I cells were labelled with 
nanoparticles carrying FITC fluorescent label (Qtracker™ 565 Cell 
Labeling Kit, Thermo Fisher Scientific). B16-OVA tumours were 
treated twice before collection on day 6 (Figure 13C). Collected 
tumours were pressed through a 70-μm strainer and the yielded cell 
suspension labelled fresh with anti-CD8 antibody. FITC positive CD8 




Figure 13. Schedule and treatment groups for cell graft trafficking experiments. 
A) Mice bearing B16-OVA melanoma were treated with cytokine-armed adenoviruses 
and the trafficking of 111Indium-oxane-labelled OT-I T cells was followed over four days. 
B) TILs were labelled similarly and followed over time in hamsters bearing two 
pancreatic HapT1 tumours. Only one of the tumours was treated with unarmed or 
armed oncolytic virus. C) Complementary to hamster experiment, OT-I cells were 
labelled with fluorescent nanoparticles and administered to animals receiving virus 
treatments to one out of two tumours. Tumours were collected on day 6 and the 
presence of fluorescent OT-I cells was analysed with flow cytometry. 
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3.5 CHEMOKINE AND CYTOKINE LEVELS IN 
TUMOURS (I AND IV) 
B16.OVA tumours were established in Study I on C57BL/6 mice, as 
previously described, to investigate the effect of viral treatment on 
the expression of chemokines. The mice received 1 x 109 VP of Ad5-
CMV-mIL2, Ad5-CMV-mTNFα, or a combination of both 
intratumourally in addition to intraperitoneal injection of OT-I cells 
(Figure 6). The tumours were snap-frozen and homogenized after a 
week. RANTES, MCP1, MIP-1a, MIG, and I-TAC were detected with 
CBA Flex Sets (BD) as guided by the producer and normalised 
against the total protein concentration of the sample. Similarly, 
endpoint B16.OVA tumours were collected in Study IV to screen the 
treatment-related changes in the cytokine profiles. CBA mouse 
Th1/Th2/Th17 kit (BD) was utilized to determine the levels of IL2, 
IL6, and TNFα. 
3.6 FLOW CYTOMETRY (I–IV) 
Tumours, spleens, and lymph nodes were collected into an RPMI 
medium with 10% FBS and pressed through a 70-μm strainer. The 
cells were incubated for 24 hours in regular cell culture conditions 
before freezing them in an RPMI medium containing 20% FBS and 
10% DMSO. Erythrocytes were lysed from the splenocyte suspension 
with ACK treatment. The cells were stored at -80°C and analysed 
immediately after thawing. Approximately 1 x 106 cells were allocated 
per well on a 96-well plate and washed once with stain buffer (PBS 
containing 0.1% BSA) 500xg for 5 min at +4°C. Pro5 MHC 
Pentamers (10 μl per reaction) were incubated with the cells at room 
temperature in dark for 20 min (SIINFEKL for OVA, KVPRNQDWL 
for gp100, and SVYDFFVWL for Trp2), followed by a wash cycle. 
Table 4 lists the antibodies that were used in concentrations 
recommended by the manufacturer and incubated for 30–60 min at 
+4°C. The cells were resuspended into stain buffer after a wash, and 





Table 4. Antibodies used for detecting immune cell subsets. The cells 
were stained with the recommended amounts of antibodies during maximum 60 
minutes. 













mouse BD I, III 
CD19-PE Rat mouse eBioscience I, III, IV 
CD25-PE Rat mouse eBioscience I, IV 




mouse BD I 
CD3-PE-Cy7 Rat mouse BD III, IV 
CD4- 
PerCP-Cy5.5 
Rat mouse eBioscience I, IV 




mouse eBioscience I 
CD86-PE Rat mouse BD I, III, IV 
CD8a-APC Rat mouse eBioscience I 
CD8b-FITC Rat mouse eBioscience I, III, IV 
CD8b-PE Mouse rat eBioscience II, IV 
F4/80-APC Rat mouse eBioscience III, IV 
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Gr-1-FITC Rat mouse BD I 








mouse eBioscience I 
 
3.7 IMMUNOHISTOCHEMISTRY (II AND IV) 
The formalin-fixed (48 hours) tissue samples were preserved in 70% 
ethanol until paraffin embedding. The samples were sectioned at 4-
μm thickness and stained with hematoxylin and eosin. A trained 
veterinary pathologist evaluated and scored the treatment-related 
histological changes, such as blood vessel abnormalities, signs of 
inflammation, and necrosis in normal tissues. 
3.8 SPLENOCYTE PROLIFERATION (II) 
The spleens were collected from the hamsters on day 25 after the 
beginning of the treatments in Study II. Splenocytes from each group 
were pooled and divided into four replicates on a 96-well plate, 10 
000 cells/well. Cells were counted from 20 μl of cell suspension with 
BD Accuri Flow Cytometer after a 72-hour incubation. The 
splenocyte count from each well was divided by the mean cell count 
in the mock wells to learn the relative proliferation rate. 
 
63 
3.9 QUANTITATIVE POLYMERASE CHAIN 
REACTION (III) 
The spread of the virus was evaluated in Study III by detecting viral 
E4 DNA copy numbers from treated and untreated mouse and 
hamster tumours, as well as from hamster hearts, lungs, livers, 
spleens, and kidneys, with qPCR (Koski et al. 2010, Kanerva et al. 
2002). Tissue samples were cut into pieces and 25 mg was used for 
the DNA extraction with QIAamp Mini Kit (Qiagen) using a QIAcube 
machine according to the manufacturer’s protocol. The single 
portion of master mix for the qPCR reaction contained 4.3 μl H2O, 
0.75 μM both primers, 0.1 μM probe and 10 μl enzyme mix from the 
kit (LightCycler 480 Probes Master, Roche). The E4 copy number 
was normalized against mouse beta-actin or hamster GAPDH. 
Table 5 summarizes the primers and probes used in the study and 
Table 6 the conditions for the PCR run. 
Table 5. Primers and probes used in qPCR (from Oligomer). The probes 
were labelled with 6’FAM 



































Table 6. Running conditions for qPCR. 
Temperature Time (mm:ss) Cycles 





40°C 10:00 1 
3.10 MESSENGER RNA SEQUENCING (III) 
The RNA samples for the evaluation of gene-expression levels on 
injected and non-injected tumours were prepared for messenger 
RNA sequencing by constructing a library with NEBNext Ultra 
Directional RNA Library Prep Kit 3 (New England Biolabs, Ipswich, 
MA, USA). The sequencing was performed by single-ended Illumina 
NextSeq High Output 1 x 75 bp sequencing (Illumina, San Diego, CA, 
USA). FastQ tool analysed the quality of the sequencing output, and 
the data were summarised and trimmed with MultiQC and 
Trimmomatic, respectively (Ewels et al. 2016, Bolger et al. 2014, 
Andrews 2010). Syrian hamster reference genome, against which the 
sample reads were aligned, was obtained from NCBI database 
(RefSeq GCF_000349665.1_MesAur1.0). The FeatureCounts tool 
was employed when quantifying the results (Liao et al. 2014). The 
expression profiles of virus-injected tumours were compared with 
saline-injected tumours. Likewise, the non-injected tumours in 
treatment groups were compared with the non-injected tumours in 
vehicle group. The statistical significance of the differences in gene-
expression levels was evaluated with DESeq (Love et al. 2014). Genes 
showing over two-fold up- or downregulation and having p<0.05 
were examined in more detail and their ontology analysed against 







3.11 REVERSE TRASCRIPTION QUANTITATIVE 
PCR (III AND IV) 
RNA was extracted from HapT1 tumours four days after treatment 
with Ad5/3-E2F-d24 or Ad5/3-E2F-d24-hIL2 to investigate whether 
treatment of hamster tumours with oncolytic virus induces 
endogenous IL2 expression. Tumour samples (30 mg) were stored in 
RNAlater (Qiagen) until disrupted as single-cell suspension. The 
RNA was extracted with an RNeasy Mini Kit (Qiagen) and 
transformed into complementary DNA with a QuantiTect Reverse 
Transcription Kit (Qiagen). Hamster IL2 was detected by qPCR with 
the following primers and probe: Forward primer 
GTGCACCCACTTCAAGCTCTAA, reverse primer 
AAGCTCCTGTAAGCTCAGCAGTAAC, and probe 6-Fam-
AGGAAACCCAGCAGCACCTCGAGC-BHQ-1. Hamster GAPDH 
expression was used for normalisation.  
Similarly, RNA samples analysed with messenger RNA 
sequencing were transcribed to cDNA with High-Capacity cDNA 
Reverse Transcription Kit (Thermo Fisher Scientific) in order to 
analyse more in detail the effect of the treatment on TGFβ and FoxP3 
expression levels. The sequences for TGFβ primers and probe were 
TGTGTGCGGCAGCTGTACA and TGGGCTCGTGAATCCACTTC for 
forward and reverse primers, respectively, and 6FAM-
CGACTTTCGCAAGGACCTGGGCT-BBQ for probe. Forward and 
reverse primers for FoxP3 were AAGCAGATCACCTCCTGGAT and 
AGCTGCTGCTCCAGAGAC, respectively and the probe sequence 
6FAM-CACCACTTCTCTCTGGAGGAGGCAC-BBQ. The qPCR 
reactions and running conditions were identical to those previously 
described.  
3.1 STATISTICAL ANALYSES (I–IV) 
The results of in vitro and ex vivo experiments were analysed with 
Student’s t-test, non-parametric Mann-Whitney test, one-way 
analysis of variance (ANOVA), or non-parametric Kruskal-Wallis 
test. The tumour growth curves were analysed over both treatment 
and time with log-linear mixed-effects model or with two-way 
ANOVA. The outcome of the treatment in Study II was evaluated by 
66 
the Wilcoxon signed rank test and the survival curves in Study III 
with log-rank test. The analyses were performed with GraphPad 
Prism 6 and 7 (GraphPad Software Inc., San Diego, CA, USA) or IBM 
SSP Statistics versions 22–24 (IBM, Armonk, NY, USA). The 
differences between the groups were considered statistically 
significant when p≤0.05. 
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4 RESULTS AND DISCUSSION 
T cell therapies show much promise against haematological 
malignancies, but efficacy on solid tumours has room for 
improvement. Solid tumours often develop resistance against T-cell 
therapies by altering antigen presentation or when tumour 
phenotype changes due to clonal selection, for example (Sharma et 
al. 2017). Oncolytic viruses enhance immunogenic cell death, epitope 
spreading, antigen presentation, and T-cell trafficking and 
infiltration, all of which are essential for successful ACT (Chen & 
Mellman 2013). Moreover, oncolytic viruses potentially enable 
treatment of tumours that developed resistance to ACT, as infection 
induces sudden and periodical antigen appearance (Pradeu et al. 
2013). Oncolytic viruses were studied here as enablers of TIL and 
TCR therapy in solid tumours. 
4.1 CONSTRUCTED VIRUSES ARE 
FUNCTIONAL IN VITRO (I, II) 
The studied viruses have a backbone of type 5 adenovirus. The 
viruses coding for murine cytokines (Ad5-CMV-mIL2, Ad5-CMV-
mTNFα, Ad5-CMV-mIFNγ, and Ad5-CMV-mIFNβ) have the 
transgenes under CMV promoter replacing E1 region, thus making 
the virus replication-incompetent (Figure 1a, Study I). The human 
transgenes were inserted into chimeric viruses bearing adenovirus 
type 5 genome with fibre knob from type 3 (Ad5/3-E2F-d24-hIL2, 
Ad5/3-E2F-d24-hTNFα, and Ad5/3-E2F-d24-hTNFα-IRES-hIL2). 
The transgene expression is linked to virus replication as the genes 
replace parts of E3 (Figure 1a, Study II). The replacement of 
adenovirus gp19k/6.7k in E3 region also makes the virus more 
immunogenic, as those proteins normally block the cell’s 
mechanisms to present antigens on their surfaces (Bennett et al. 
1999).  
The oncolytic viruses were able to lyse a panel of human and 
hamster cell lines (Figure 1b and Supplementary Figure S1, Study II), 
and the effect was more pronounced when combined with TILs 
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(Figure 1c, Study II). Syrian hamsters are semipermissive for 
adenovirus replication (Thomas et al. 2006), and in this study, the 
cell line lysis required five to ten times more virus than human cell 
lines (Figure 1b, Study II). 
Both human and mouse cytokines produced from adenoviruses 
were biologically active in vitro and in vivo (Figure 1 and 
Supplementary Figure S1, Study I; Figure 2 and Supplementary 
Figure S2, Study II). Importantly, the transgene expression 
remained local in vivo and only negligible levels of IFNs appeared in 
mouse sera (Figure 1c–f, Study I; Figure 2c, Study II). The control 
virus expressing luciferase induced IL2, TNFα, and IFNγ expression 
in mouse tumours, indicating that the virus infection itself promotes 
immunological reactions (Figure 1c–f, Study I). The cytokine levels 
were more pronounced, however, when delivered within a virus. 
Treatment with oncolytic viruses did not induce the expression of 
endogenous IL2 in hamsters (Supplementary Figure S1, Study IV). 
As the viruses carry cytokines that are extremely toxic when 
administered systemically in high doses, local production is an 
important safety aspect (Schwartz et al. 2002, Schiller et al. 1991).  
4.2 ANTITUMOUR EFFICACY OF THE 
ONCOLYTIC VIRUS IS DOSE DEPENDENT 
(II) 
To establish effective dose for Ad5/3-E2F-d24-hTNFα-IRES-hIL2, 
immunocompromised mice bearing orthotopic human ovarian 
cancer (SKOV3-Luc) received systematically 105, 107, or 109 VPs 
(Figure 3a, Study II). A statistical significance existed between the 
highest and the lowest dose and, as expected with 
immunocompromised animals, adenovirally-delivered cytokines did 
not add to antitumour efficacy (Figure 3b and c, Study II). Moreover, 
the result indicates that the arming device does not compromise the 
lytic capability of the virus in vivo. 
The tumours escaped from the growth control over time (Figure 
3b, Study II). The phenomenon is typical for this model: SKOV3-Luc 
cells upregulate IFN signalling pathways when generating resistance 
against oncolytic adenoviruses (Liikanen et al. 2011). In addition to 
IFN pathway, Cancer Upregulated Gene 2 relates to cancer cell 
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resistance against oncolytic viruses via STAT1 signalling (Moerdyk-
Schauwecker et al. 2013, Malilas et al. 2013). The phenomenon 
describes the core problem with any cancer treatment: Eradication 
of vulnerable clones induces emergence of the resistant clones 
(Sharma et al. 2017). To overcome the problem, combinational 
treatments are used to attack the tumour from multiple angles. In 
this study, oncolytic viruses were combined with ACT. 
4.3 ARMING AN ADENOVIRUS WITH A 
CYTOKINE IMPROVES ADOPTIVE CELL 
THERAPIES (I, II) 
We employed black C57BL/6 mice bearing subcutaneous B16.OVA 
melanoma as an immunocompetent mouse model. The cell line 
expresses chicken ovalbumin, which enables the engagement of OT-
I T cells against OVA extracted from a TCR transgenic mouse. Hence, 
the ACT approach in mice represents TCR therapy. As human 
adenovirus replicates poorly in mice (Blair et al. 1989), the 
experimental settings lack the effect of oncolysis. Oncolytic viruses 
were studied in Syrian hamsters, where human IL2 and TNFα are 
also active (Gowen et al. 2008, Memon et al. 1997). Moreover, we 
have established a method to extract TILs from various hamster 
tumours (Siurala et al. 2016). 
Regarding replication-incompetent viruses coding for murine 
cytokines, IL2 and IFNγ improved TCR therapy the most (Figure 2, 
Study I). The difference between TNFα alone and TNFα together 
with OT-I failed to reach statistical significance even though the 
combination showed the most pronounced antitumour efficacy 
(Figure 2b, Study I). The only virus failing to improve TCR therapy 
was Ad5-CMV-mIFNβ (Figure 2d, Study I). TNFα and IL2 were 
chosen for closer investigations based on these and previous results 
with recombinant cytokines (Tahtinen et al. 2015). 
TNFα has direct antitumour effects when inducing cancer cell 
apoptosis and necrosis, but it also induces expression of T-cell 
attracting chemokines (Mocellin et al. 2005). IL2 has more direct 
effects on T cell proliferation and differentiation (Liao et al. 2013). 
Separate adenoviral delivery of both cytokines has been studied in 
cancer patients. Local delivery of TNFα in replication-incompetent 
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adenoviruses (TNFerade) has been well tolerated and resulted in 
complete responses in four out of 16 cancer patients (McLoughlin et 
al. 2005). However, the treatment has not been enough to prolong 
survival of pancreatic cancer patients compared with the standard of 
care (Herman et al. 2013). Local injection of adenovirus coding for 
IL2 (TG1024 and AdCAIL-2) has also been safe and resulted in some 
complete responses (Dummer et al. 2008, Trudel et al. 2003, Stewart 
et al. 1999). Moreover, the local treatment increases the presence of 
CD8+ T cells in tumours, which is an important indicator for efficacy 
(Dummer et al. 2008, Trudel et al. 2003, Stewart et al. 1999). 
The combination of Ad5-CMV-mTNFα and Ad5-CMV-mIL2 
enhanced the OT-I TCR therapy the most when compared with both 
viruses administered alone (Figure 3, Study I). Without OT-I 
treatment, the combination of the viruses resulted in as good 
antitumour efficacy as Ad5-CMV-mIL2 alone or together with OT-I 
(Figure 3, Study I). Ad5-CMV-mTNFα did not have as good 
antitumour efficacy as did Ad5-CMV-mIL2 in this experiment. 
Oncolytic viruses in hamsters did not reveal big differences in 
efficacy between viruses coding for only one cytokine and the virus 
coding for both human TNFα and IL2 (Figure 4b-c, Study II). TIL 
therapy alone did not have antitumour efficacy, but when combined 
with unarmed oncolytic adenovirus, some of the tumours were even 
cured (Figure 4a and e, Study II). Armed viruses were also effective 
as single agents, but combining TIL treatment with Ad5/3-E2F-d24-
hIL2 or Ad5/3-E2F-d24hTNFα-IRES-hIL2 cured 100% of the 
animals (Figure 4e, Study II). The cure rate in groups treated with 
armed viruses only remained between 55% and 85% (Figure4e, 
Study II). The results were similar even with lowered virus dosages 
(Figure 4f, Study II).  
The combination of recombinant TNFα and IL2 administered 
systemically to non-small-cell lung cancer patients has generated 
modest responses, even though preclinical data has shown much 
promise (Yang et al. 1990, McIntosh et al. 1988, Winkelhake et al. 
1987). The biggest obstacle in using recombinant cytokines is the 
balance between efficacy and systemic toxicity, which is why tumour-
targeted delivery is preferred today. The delivery of IL2 and TNFα as 
antibody fusion proteins has also resulted in higher antitumour 
efficacy in combination than as single agents (Pretto et al. 2014). 
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Moreover, in vitro and in vivo results show that in this setting, TNFα 
plays an important role in tumour eradication, as do both cytokines 
in immune reactions and T-cell stimulation (Menssen et al. 2018). 
4.4 COMBINATION OF IL2 AND TNFΑ MODIFIES 
IMMUNE CELL PROFILES IN TUMOURS (I, II, 
III) 
The presence of tumour-infiltrating T cells is an important 
prognostic factor in clinic, and the efficacy of many treatments relies 
on inducing the T-cell infiltration (Geng et al. 2015, Ibrahim et al. 
2014). The infiltration is improvable to some extent with 
conventional treatments like chemotherapy, but immunotherapies 
are more potent in this regard (Oelkrug & Ramage 2014). Oncolytic 
adenoviruses induce infiltration of a variety of immune cells in 
clinical trials: Specifically, M1 macrophages, CD8+ effector T cells, 
Th1 helper T cells, and B cells are abundantly present in tumour 
samples after treatment with oncolytic adenovirus (Lang et al. 2018, 
Ranki et al. 2016, Vassilev et al. 2015). 
4.4.1 VECTORED DELIVERY OF IL2 AND TNFΑ INDUCES T 
CELL, NK CELL, AND ANTIGEN PRESENTING CELL 
INFILTRATION AND ACTIVATION (I, III) 
The results show that IL2-armed adenovirus modulates the immune 
cell populations in tumours the most when compared with an 
unarmed or TNFα-armed adenovirus (Figure 4, Study I; Figure 5a-e, 
Study II; Figure 3, Study III). The addition of a therapeutic cell graft 
did not alter the immune cell profiles (Figure 4, Study I; Figure 5a-e, 
Study II). Having IL2 in the treatment virus increased the proportion 
of CD4+ and CD8+ T cells, activated T cells, and B cells in mouse 
tumours on day 18, and also Tregs to some extent (Figure 4a-e, Study 
I). Even though cytotoxic CD8+ cells often receive more attention in 
regard to treatment efficacy, recent studies have shown that CD4+ 
cells might have even bigger role in patients responding to 
immunotherapies (Spitzer et al. 2017).  
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Unlike on day 18 samples, the levels of tumour-specific T cells 
were not statistically significantly increased on day 8 (Figure 3e, 
Study III). T cell and NK cell levels were similar in groups treated 
with IL2 alone or with both IL2 and TNFα, but the combination 
might induce lymphokine-activated killer cells and NK cells better 
than IL2 alone (Schultz et al. 1994, Favrot et al. 1990, Yang et al. 
1989).  
The level of NK cells was increased at both time points, on days 8 
and 18 (Figure 4f, Study I; Figure 3a, Study III). NK cells have an 
important role in eradicating tumours with poor HLA class I 
expression, which is common in many cancers (Geller & Miller 2011). 
Moreover, both TNFα and IL2 are essential for NK cell activation, 
which highlights the importance of this cell population in regard to a 
therapy employing both of these cytokines (Balasa et al. 2015). NK 
cells are also essential for tumour-associated antigen presentation on 
dendritic cells and dendritic cells stimulate NK cell priming 
(Deauvieau et al. 2015, Lucas et al. 2007).  
Importantly, we saw a positive correlation between the presence 
of NK cells and dendritic cells in mouse tumours (Supplementary 
Figure S2, Study III).  IL2 especially induced the presence of mature 
dendritic cells at an earlier time point, but on day 18 the increased 
levels were observed in groups treated with both cytokines or the 
combination of viruses and OT-I cells (Figure 3b, Study III; 
Supplementary Figure S2b, Study I). 
TNFα had a clear effect on macrophages: Treatment with any 
virus induced the presence of macrophages, but the effect was most 
prominent in tumours treated with TNFα-armed virus (Figure 3c, 
Study III). Importantly, even though TNFα increased the level of 
macrophages in tumours, it decreased the level of 
immunosuppressive M2 phenotype at an early time point (Figure 3d, 
Study III), a phenomenon also reported elsewhere (Kratochvill et al. 
2015). On day 18, the level of M2-like macrophages was slightly 
increased in tumours treated with Ad5-CMV-mTNFα or Ad5-CMV-
mIL2 (Supplementary Figure S2a, Study I). However, when these 
two viruses were administered together, the levels corresponded to 
the control group receiving TCR therapy alone. 
Treating mice with TCRs increased the proportion of cells 
expressing PD-L1 in tumours, and the addition of armed viruses 
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further promoted that effect (Figure 5a, Study I). Closer investigation 
of PD-L1-expressing cells in mice developing spontaneous 
melanoma suggests that Ad5-CMV-mIL2 or Ad5-CMV-mTNFα 
induces PD-L1 especially on MDSCs and not on cancer cells 
(Tahtinen et al. 2016). Increased levels of PD-L1 might also relate to 
the increased levels of activated T cells producing IFNγ in tumours 
(Tumeh et al. 2014). In addition, we observed downregulation of PD-
1 expressing CD8+ T cells after treatment with viruses coding for IL2, 
yet the difference was not statistically significant (Figure 5b, Study 
I). PD-1 is a contradictory marker, since it functions as part of a 
negative feedback loop on activated T cells (Shi et al. 2013). Hence, 
the cells expressing PD-1 are cytotoxic but more prone to PD-L1-
mediated silencing. In the presence of constant IL2 expression, 
however, T cells might be more resistant to silencing (Sultan et al. 
2018). 
4.4.2 ARMED ONCOLYTIC VIRUS INDUCES 
IMMUNOLOGICAL CHANGES IN TUMOURS BOTH ON 
CELL AND GENE EXPRESSION LEVEL (II, III) 
Similar changes in tumour-infiltrating immune cell populations were 
observed in hamsters treated with oncolytic viruses than were 
observed in mice treated with replication-incompetent viruses. 
Tumours treated with IL2-armed viruses had bigger portions of 
CD8+ and CD4+ T cells in addition to GM1+ cells that are mainly NK 
cells (Figure 5a, b, e, Study II). Studies investigating TNFα and IL2 
fused to an antibody suggest that the cytokine combination induces 
mostly CD4 helper cells and cytotoxic CD8 cells (Balza et al. 2010), 
but the lack of reagents hindered a more detailed characterization of 
T cells in this study. Therefore, we evaluated treatment-induced 
immunological changes in tumours with messenger RNA sequencing 
from day 10 tumours treated with Ad5/3-E2F-d24-hTNFα-IRES-
hIL2 or Ad5/3-E2F-d24. 
Compared with vehicle injection, Ad5/3-E2F-d24-hTNFα-IRES-
hIL2 and Ad5/3-E2F-d24 upregulated 114 and 404 genes over two 
fold, respectively (Figure 5 and Supplementary Figure S3, Study III). 
Over two-fold downregulation was rarer: Six genes with Ad5/3-E2F-
d24-hTNFα-IRES-hIL2 and 28 with Ad5/3-E2F-d24 (Figure 6 and 
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Supplementary Figure S3, Study III). Similar to mouse tumours, 
virus injection upregulated genes belonging to NK cell activation 
markers such as Mertk, Coro1a, Pglyrp2, Slamf6, Ptpn22, Gas6, 
Itgb2, Il21r, Cd244, Pik3cd, Rab27a, Prdm1, Slamf1, Havcr2, and 
Cd2 (Supplementary figure S5, Study III). Likewise, genes clustering 
to dendritic cell differentiation markers (Dock2, Irf4, Cd244, Slamf1, 
Spi1, Havcr2, Cd2) were upregulated upon virus treatment 
(Supplementary Fig. S5, Study III). 
Treatment with viruses had little effect on antigen-presenting 
immune cells in hamster tumours, as there were negligible changes 
in the levels of MHC class II or Mac-2 expressing cells when analysed 
by flow cytometry (Figure 5c, d, Study II). On gene expression level, 
however, we saw upregulation of macrophage marker Scara5 (Figure 
5, Study III). Tumours treated with Ad5/3-E2F-d24-hTNFα-IRES-
hIL2 also expressed a panel of M1 macrophage-related genes and 
lacked most of the signature genes for M2 macrophages (Kratochvill 
et al. 2015). Thus, the gene expression profiles reflect the results 
obtained from mice with flow cytometric analyses (Figure 3, Study 
III). 
Patel et al. (2017) recently reported a panel of genes especially 
important for successful immunotherapies. Interestingly, the 
unarmed Ad5/3-E2F-d24 was able to upregulate many of these 
genes: We saw upregulation of T cell marker Aplnr and B2m, Tap1, 
Tap2, and Tapbp that are related to HLA class I antigen processing 
and presentation (Supplementary Figure S4, Study III). The lack of 
these specific genes counteracts the efficacy of immunotherapies 
(Patel et al. 2017). Upregulation of genes related to antigen 
presentation is especially important, because this pathway is often 
malfunctional in tumours (Geller & Miller 2011). 
Compared with unarmed Ad5/3-E2F-d24, tumours treated with 
Ad5/3-E2F-d24-hTNFα-IRES-hIL2 uniquely upregulated cytokine 
genes Csf3 and Il1b, macrophage marker Marco and atypical 
chemokine receptor gene Ackr3 (Figure 5, Study III). IL1β is an 
important cytokine in regard to TILs, as it shifts the Th17 helper cell 
phenotype from immunosuppressive to effector (Chatterjee et al. 
2014). Macrophage-derived MARCO has recently been identified as 
a receptor for adenovirus type 5 that binds the receptor with hexon 
protein (Stichling et al. 2018). Macrophages commonly allow 
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replication of many pathogens, which then enhances the pathogen 
eradication and guides further immune reactions (Price & Vance 
2014).  
4.5 CYTOKINE-ARMED ADENOVIRUSES 
INDUCE CELL GRAFT TRAFFICKING INTO 
TREATED TUMOURS (I, III) 
Virus coding for TNFα was especially important for inducing 
chemokine expression in tumours (Figure 5c, Study I). For this 
reason, we sought to investigate systemically administered 
therapeutic cell graft trafficking into locally treated tumours. OT-I T 
cells or hamster TIL graft were radiolabelled with 111In-oxine and the 
trafficking of the cells was followed over time. The combination of 
IL2 and TNFα was the most efficient in recruiting the cells into 
mouse tumours (Figure 6, Study I). At earlier time points, 24 and 48 
hours after cell administration, tumours treated with TNFα-
encoding virus had the highest levels of engrafted cells, but the 
combination of the cytokines was essential for persistent presence of 
the cells until 96 hours after treatment (Figure 6, Study I). The signal 
obtained from the vehicle-treated tumours weakened over the time 
of observation both in mouse and in hamster tumours (Figure 6a, 
Study I; Figure 4a, Study III). 
The combination of TNFα and IL2 was compared with unarmed 
virus in the oncolytic setting with TILs. The results were similar to 
those obtained with replication-incompetent viruses in mice: The 
arming device was necessary for cell graft persistence in tumours 
(Figure 4a and c, Study III). Even though the unarmed virus was 
capable of recruiting TIL graft into a tumour, the levels decreased 
over time, similar to vehicle treatment (Figure 4a, Study III). Overall, 
both TNFα and IL2 have important roles regarding ACT graft 
trafficking: TNFα attracts T cells into tumours, while IL2 enables 
their persistence (Sultan et al. 2018, Calcinotto et al. 2012, 
Johansson et al. 2012). 
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4.6 ARMING AN ADENOVIRUS WITH 
CYTOKINES INDUCES SYSTEMIC 
ANTITUMOUR EFFECTS (II, III) 
Even though positive changes in immune cell milieu in a tumour 
microenvironment are essential for successful immunotherapy, 
systemic changes are at least as important (Spitzer et al. 2017). In 
this study, tumour-draining lymph nodes had lower levels of CD8+ 
cells when the animals received cytokine-armed viruses 
(Supplementary Figure S3a–c, Study II). The spleens of these 
animals had a decreased level of CD4+ cells and a mild increase of 
MHC class II+ cells (Supplementary Figure S3d–e, Study II). The 
levels were the opposite of the immune cell populations in tumours, 
reflecting the possible trafficking of the cells from the reservoirs to 
the site of action. Moreover, the splenocytes extracted from animals 
treated with cytokine-armed viruses showed increased activity ex 
vivo as measured by the proliferation rate (Figure 5f, Study II). 
Interestingly, the unarmed Ad5/3-E2F-d24 did not induce the same 
effect. When animals were cured with cytokine-armed viruses, they 
had developed immunological memory against the same tumour cell 
type (HapT1) but not against a foreign cell type DDT1-MF2 (Figure 
6, Study II). Treatment with an unarmed virus cured one animal that 
was only partially protected against new tumours. 
Based on these results, we studied whether local treatment could 
induce the systemic antitumour effect known as the abscopal effect. 
Syrian hamsters bore two tumours on their flanks, only one of which 
received injections of Ad5/3-E2F-d24-hTNFα-IRES-hIL2 or the 
control viruses. All oncolytic viruses had a similar antitumour 
efficacy in injected tumours, as previously noted (Figure 1a, Study 
III). Interestingly, the cytokine-armed viruses also restricted the 
growth of non-injected tumours, whereas the unarmed virus was not 
as efficient (Figure 1b, Study III). Low levels of viral DNA were 
present in non-injected tumours, indicating the virus was trafficking 
from injected tumours via blood circulation (Figure 1c, Study III). 
Small quantities of virus DNA were also found in hamster lungs, 
heart, spleen, liver, and kidneys, and there were no differences 
between the viruses in this regard (Supplementary Figure S1A, Study 
III). Previous studies with analogous capsid construct indicate 
similar distribution of the virus in patients (Koski et al. 2015). 
 
77 
Despite the system-wide distribution of the virus, hamsters 
treated with Ad5/3-E2F-d24-hTNFα-IRES-hIL2 survived over 120 
days – more than three times longer than the untreated animals 
(Supplementary figure S1b, Study III). The humane endpoint criteria 
(mainly tumour size and ulceration) determine survival in 
subcutaneous tumour models, but it is also an important indicator 
for the systemic toxicity of the treatment. We did not observe any 
major treatment-related histological changes, such as blood vessel 
abnormalities, signs of inflammation, or necrosis, in hamster lungs, 
hearts, spleens, livers, or kidneys on day 25 after five treatments with 
any of the viruses (Supplemental Materials and Methods, Study II). 
Hence, despite the fact that the virus is able to penetrate distant 
organs, it does not cause systemic toxicity in animals. 
Partly because of virus spread, tumour growth reduction was 
equally good in injected and non-injected tumours (Figure 1d, Study 
III). Treatment with oncolytic herpes virus, T-vec, has induced a 
similar abscopal effect, but the virus does not spread to distant 
tumours (Moesta et al. 2017). The response rate to local treatment in 
patients reaches 26% in injected tumours and 15% in non-injected, 
which derives, thus, mainly from the immunological effects induced 
by oncolysis and the transgene GM-CSF (Andtbacka et al. 2015).  
The transgenes also had a major effect on systemic efficacy in our 
study. One out of two B16.OVA tumours on immunocompetent mice 
received replication-incompetent Ad5-CMV-mTNFα, Ad5-CMV-
mIL2, or the combination of these two. Tumour growth was followed 
until an early time point, day 8. Injected tumours were around 30% 
of the size of vehicle-treated tumours by this day, whereas the non-
injected tumours in the group receiving the combination of TNFα- 
and IL2-armed viruses resulted in 50% growth reduction (Figure 2a 
and b, Study III). The addition of TCR treatment did not provide 
additional efficacy during this short experiment (Figure 2c and d, 
Study III). The experiment was repeated and again, even though the 
tumour growth control was not visible on the injected tumours due 
to inflammation on day six, the non-injected tumours in group 
receiving cytokine-coding viruses were clearly smaller than the 
control tumours (Figure 2e and f, Study III). The virus did not spread 
to distant tumours in this model, indicating the importance of the 
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transgenes (Figure 2g, Study III); hence, the efficacy derives from 
both the virus spread and the transgenes. 
Interestingly, virally delivered transgenes induced 
immunological changes also in the non-injected tumours (Figure 3, 
Study III). Non-injected tumours had significantly increased levels 
of NK cells and macrophages compared with vehicle treated tumours 
(Figure 3a and c). IL2 especially induced the presence of mature 
dendritic cells in injected tumours, but the levels failed to achieve 
statistical significance in non-injected tumours (Figure 3B, Study 
III). Similarly, the level of immunosuppressive M2 macrophages was 
lowered in tumours injected with cytokine-armed viruses, but not 
significantly in non-injected tumours, despite a clear trend (Figure 
3d, Study III). There were no differences in melanoma-specific T 
cells in either injected or non-injected tumours (Figure 3e, Study III). 
In addition to inducing similar immune cell milieus in injected 
and non-injected tumours, treatment of one tumour induced TIL 
graft trafficking also to the non-injected tumour (Figure 4b and c, 
Study III). Small number of replicates, however, prevents the 
statistical evaluation of the results. Nevertheless, the signal obtained 
from the tumours in groups receiving vehicle or unarmed virus 
seemed to decrease over time, whereas the signal from the group 
treated with Ad5/3-E2F-d24-hTNFα-IRES-hIL2 remained the same 
(Figure 4a and b, Study III). Importantly, complementary data from 
mice treated with replication-incompetent viruses point to the same 
direction: Injection of one tumour induced T-cell graft trafficking 
also to the non-injected tumour (Figure 4d, Study III). This and other 
results suggest that besides oncolysis, the cytokine arming-device 
plays a crucial role in the treatment efficacy.   
Because of limited amount of reagents for hamster studies, we 
sought to investigate the mechanisms behind the observed abscopal 
effect from gene-expression profiles. The results in mice indicated 
the importance of chemokines in TCR cell graft trafficking. In 
hamsters, we saw unique upregulation of chemokines Cxcl5 and 
Rnase2 in the group treated with Ad5/3-E2F-d24-hTNFα-IRES-
hIL2 (Supplementary Table S2, Study III), but to current knowledge 
from humans, more than T cells they attract neutrophils and 
dendritic cells, respectively (Rosenberg 2015, Zhou et al. 2012). 
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4.6.1 LOCAL INJECTION WITH ARMED ONCOLYTIC VIRUSES 
UPREGULATES IMMUNITY-RELATED GENES IN 
DISTANT TUMOURS (III) 
In addition to chemokines, unarmed Ad5/3-E2F-d24 and Ad5/3-
E2F-d24-hTNFα-IRES-hIL2 induced expression of several immune- 
related genes in injected and non-injected tumours (Figure 5 and 6, 
Supplementary Figure S3–S6, Study III). The hamsters were treated 
on days 1 and 8, and the samples were collected on day 10. Control 
animals receiving saline injections to one tumour served as a baseline 
sample. The gene expression of saline-injected tumours was 
compared with that of non-injected tumours to resolve the effect of 
injection itself. Not surprisingly, the gene-expression profile 
revealed that a needle puncture and an injection with the vehicle also 
induced responses related to immune system regulation and 
downregulated cytoskeleton and cell-cell adhesion molecules 
(Supplementary Table S1, Study III). 
TIL treatment alone upregulated 101 genes and downregulated 35 
genes in tumours that were injected with saline (Figure 5 and 6, 
Supplementary Figure S3, Study III). When the tumour was not 
injected, 136 genes were upregulated and 53 downregulated (Figure 
5 and 6, Supplementary Figure S3, Study III). TIL treatment 
upregulated 17 genes in both tumours compared with vehicle 
treatment, regardless of injection. The most interesting genes among 
these are chemokine Ccl11, T-cell specific Slamf9, complement C6, 
and macrophage surface marker Siglec1. The results offer hints of the 
immunological changes TIL treatment can achieve: T-cell 
recruitment and antigen-presentation enhancement by 
macrophages. Interestingly, TIL treatment upregulated immune 
checkpoint molecule genes Pdl1 and Lag3, which was not observed 
in virus-treated animals. 
In non-injected tumours, Ad5/3-E2F-d24-hTNFα-IRES-hIL2 
and Ad5/3-E2F-d24 upregulated 17 and 61 genes and downregulated 
12 and 21 genes, respectively (Figure 5 and 6, Supplementary Figure 
S3, Study III). Treatment with Ad5/3-E2F-d24-hTNFα-IRES-hIL2 
resulted in more pronounced systemic antitumour efficacy, which is 
why the differentially expressed genes in non-injected tumours in 
this group are especially interesting. The tumours upregulated B-cell 
related genes Pou2af1, Mzb1, and Jchain, in addition to 
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immunoglobulin-like genes that have not yet been fully characterised 
(Figure 5, Study III). Thus, not surprisingly, B cells seem to have an 
importance in mediating systemic antitumour effects. Similarly, high 
B cell levels were observed in mouse tumours treated with IL2 
encoding viruses (Figure 4e, Study I and Figure 3g, Study IV). 
Downregulated genes in non-injected tumours in the group treated 
with Ad5/3-E2F-d24-hTNFα-IRES-hIL2 included heat shock 
protein genes Hspb1 and Cryab, more commonly muscle-related 
Ckm, Ca3, Mylof, Myh2, Myh3, Casq2, Csrp3, and Xirp1, 
Thrombospondin 4 (Thbs4), and T cell-attracting chemokine Ccl21 
(Figure 6, Study III). Thus, the downregulated genes do not shed 
much light on the mechanisms behind systemic efficacy. 
4.7 SYSTEMIC ADMINISTRATION OF 
RECOMBINANT IL2 IS REPLACEABLE WITH 
VECTORED DELIVERY (IV) 
Current ACT protocols usually include systemic administration of 
recombinant IL2 after the cell infusion (Besser et al. 2013). 
Unfortunately, the toxicity of the cytokine often hinders the 
treatment’s efficacy (Schwartz et al. 2002). Vectored delivery, 
however, has usually been well-tolerated (Dummer et al. 2008, 
Trudel et al. 2003, Stewart et al. 1999); hence, we studied whether 
local delivery of IL2 in an adenovirus vector could replace the need 
for systemic IL2 in regard to TIL and TCR therapy.  
Oncolytic virus coding for IL2 (Ad5/3-E2F-d24-hIL2) with TIL 
treatment restricted hamster tumour growth more than continuous 
systemic administration of recombinant cytokine (Figure 1, Study 
IV). Moreover, when the local delivery was studied in mice where the 
virus does not replicate, the effect was even more pronounced 
(Figure 2a, Study IV). The IL2 levels were higher in tumours and 
lower in serums when the cytokine was delivered in an adenovirus 
vector than they were with systemic administration of recombinant 
IL2, which is important for treatment safety (Figure 2b, Study IV). 
Vectored delivery of IL2 stimulated immune cell populations in 
tumours as well as – or even more than – the systemically delivered 
IL2 (Figure 3, Study IV). Recombinant IL2 increased the level of 
CD4+ cells in hamster tumours, which was not seen with vectored 
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delivery on day 19 (Figure 3a, Study IV). The specific subtype of these 
CD4+ cells could not be investigated due to limitations in reagent 
availability. However, in mice the systemic administration of IL2 
induced Treg population by day 9 (Figure 3h, Study IV), which is a 
well-known problem with IL2 (Ahmadzadeh & Rosenberg 2006). On 
the contrary, Ad5/3-E2F-d24-hIL2 promoted the presence of CD8+ 
cells in hamster tumours slightly better than the recombinant 
protein (Figure 3b, Study IV). Both ways of cytokine delivery induced 
the presence of CD8+ cells equally well in mice (Figure 3c, Study IV).  
There were no statistical differences in the levels of T cell 
populations recognising tumour antigen OVA or gp100 between the 
treatments (Figure 3d and e, Study IV). However, the virus was 
essential for increased levels of M1 macrophages and B cells in 
tumours (Figure 3f, and g, Study IV). B cells are especially important 
for CD4+ and CD8+ T-cell functionality (DiLillo et al. 2010), which, 
together with lower levels of Tregs, might partly explain the 
superiority of vectored delivery of IL2 over systemic administration. 
Similar changes in tumour-infiltrating immune cell subsets were 
observed in patients treated with type 5/3 chimeric adenovirus, 
coding for GM-CSF correlating with survival (Ranki et al. 2016, 
Vassilev et al. 2015).  
Overall, the virus coding for IL2 was able to induce more positive 
changes in immune cell populations in tumours than the 
recombinant protein. This might reflect the so-called bystander 
effect, in which the virus promotes the attack against both infected 
and uninfected cancer cells (Cassady et al. 2016). 
4.7.1 LOCAL DELIVERY OF IL2 IN AN ADENOVIRUS IS 
SAFER THAN SYSTEMIC DELIVERY OF RECOMBINANT 
PROTEIN (IV) 
The vectored delivery of IL2 was safer than the systemic treatment 
when evaluating the treatment-induced histological changes in vital 
organs (Figure 4 and 5a, Table 1, Study IV). Recombinant IL2 caused 
extramedullary hematopoiesis in livers and spleens, and it induced 
necrosis and histiocytosis in hamster splenic ligaments (Table 1, 
Study IV). The arteries in mouse lungs had thickened muscular walls 
and narrowed lumina because of reactive endothelial cells (Figure 5a, 
82 
Study IV). Importantly, these histological changes were not visible in 
animals treated with IL2-encoding viruses (Table 1, Study IV).  
IL2 often damages human hearts, lungs, kidneys, and central 
nervous systems, and the cause of toxicity is usually lymphoid 
infiltration or vascular leakage (Schwartz et al. 2002). IL2 also 
induces production of other cytokines that cause further damage. We 
observed increased levels of inflammation-indicating cytokines 
(TNFα, IL6, and IFNγ) in serums of animals treated with 
recombinant IL2 but not with Ad5-CMV-mIL2 (Figure 5b, Study IV). 
All these cytokines have major effects on vasculature, explaining the 
changes seen on mouse lungs (Sivakumar et al. 2013). Overall, IL2 
administration in a virus vector compared with systemic delivery of 




5 SUMMARY AND CONCLUSIONS 
This study presents a novel oncolytic adenovirus Ad5/3-E2F-d24-
hTNFα-IRES-hIL2 designed to improve a variety of T-cell related 
therapies, including ACT and checkpoint inhibitors. The results 
indicate that the virus induces both local and systemic antitumour 
effects, and the effect is even more pronounced with therapeutic cell 
grafts. The effect derives from both infection and the 
immunostimulatory transgenes. The oncolysis is necessary for the 
virus to spread to distant tumours, whereas the transgenes induce 
system-wide immunological changes. The armed virus attracts cell 
grafts into tumours but also boosts existing immunity. The virus 
induces dendritic cell maturation, directs macrophage polarisation 
towards inflammatory M1 phenotype, and promotes cytotoxic T cells. 
Treatment with armed oncolytic virus did not induce histological 
changes in normal tissues or cause systemic toxicity. Moreover, 
oncolytic adenovirus carrying IL2 could make current ACT protocols 
safer by replacing the need for systemic administration of IL2. A 
phase I clinical trial investigating the efficacy of Ad5/3-E2F-d24-
hTNFα-IRES-hIL2 with TIL treatment will be carried out in 
melanoma patients.  
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6 FUTURE PROSPECTS 
The future of cancer therapies lies in combinational treatments. 
Since each individual tumour is unique and constantly evolving 
according to Darwinian selection, cancer is an especially difficult 
disease to overcome from one treatment angle (Sharma et al. 2017). 
Immunotherapies provide an intriguing option, as they not only 
target the tumour itself but they also stimulate the patient’s own 
body to fight the disease. 
The journal Science already selected cancer immunotherapy as 
“Breakthrough of the year” in 2013, and new strategies are emerging 
in the field annually (Couzin-Frankel 2013). For example, this year 
Sockolosky et al. reported a new design for engineered T cells: 
orthogonal IL2 receptor and a cytokine that communicates the native 
IL2 signal in engineered T cells but does not activate the signalling 
elsewhere (Sockolosky et al. 2018). This blocks the unwanted effects 
of IL2 yet provides activation where it is essential. 
The hunt for novel checkpoint inhibitors is also active. For 
example, TIM-3, LAG-3, BTLA, TIGIT, VISTA, and B7-H3 have 
recently raised interest (Marin-Acevedo et al. 2018). Like PD1 and 
CTLA-4, TIM-3, LAG-3, BTLA, and TIGIT are expressed on T cells, 
whereas VISTA and B7-H3 are expressed mainly on antigen-
presenting cells (Marin-Acevedo et al. 2018). However, the results 
from clinical trials investigating the blockade of these receptors are 
still pending.  
Checkpoint inhibitors currently work well in immunologically 
active, hot tumours, but poorly in immunologically silent, cold 
tumours. Hence, they could benefit from the companionship of 
oncolytic viruses able to turn cold tumours hot. One of the emerging 
checkpoint inhibitors that could have synergistic effects with Ad5/3-
E2F-d24-hTNFα-IRES-hIL2 is B and T lymphocyte attenuator, 
BTLA. Oncolytic adenoviruses stimulate B and T cells, but if the cells 
start expressing BTLA, their activity is impaired. Of note, BTLA is 




Regarding cytotoxic cells, T cells obtain much attention but also 
NK cells form an intriguing subset. Allogenic NK cell transplant does 
not cause graft-versus-host disease, and the cells can recognise 
malignant cells without antigen presentation (Mehta & Rezvani 
2018, Ames & Murphy 2014). Currently, CAR-NK cells are under 
development to make the treatment more targeted, and the approach 
is now studied in five independent trials (Mehta & Rezvani 2018). 
Transferred NK cells have a restricted life span; thus, they could also 
benefit from local constant expression of immunostimulatory 
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